Clinical Biochemistry in the Diagnosis of Liver and Kidney Disorders: Advances in Biomarker Utilization

Editors

Nabaa Gasib Khazal Hassan
Department of Chemistry, College of Science, University of Baghdad, Iraq

Shaker Khalif Youssef Shaker
Department of Chemistry, College of Science, Tikrit University, Iraq

Marwa Hussein Shaker Saad
Department of Chemistry College of Science for Women, University of Baghdad, Iraq

Abdullah Irhaem Ali Hassan
Department of Applied Chemistry, College of Applied Seiences, University of Samarra, Iraq

Ameer Abdul Kareem Ohayid Kazim
, Department of Chemistry, College of Science University of Tikrit, Iraq

Bright Sky Publications ™
New Delhi

Published By: *Bright Sky Publications*

Bright Sky Publication
Office No. 3, 1st Floor,
Pocket - H34, SEC-3,
Rohini, Delhi, 110085, India

Editors: *Nabaa Gasib Khazal Hassan, Shaker Khalif Youssef Shaker, Marwa Hussein Shaker Saad, Abdullah Irhaem Ali Hassan and Ameer Abdul Kareem Ohayid Kazim*

Edition: *1st*

Publication Year: *2025*

Pages: *92*

Paperback ISBN: *978-93-6233-214-1*

E-Book ISBN: *978-93-6233-709-2*

DOI: *https://doi.org/10.62906/bs.book.459*

Price: *₹476/-*

Abstract

Biomarker-guided decision making is essential for the effective diagnosis and management of both liver- and kidney-related disorders. Conventional clinical biochemistry has well-defined roles in detecting liver and kidney damage; although additional markers continue to emerge, these established tests remain critical to the interpretation of novel candidates. Because the liver and kidneys are fundamental organs involved in biotransformation and excretion, routine analyses of substrates and products provide insights into the state of the overall metabolic machinery, thereby assisting in the identification of the most likely affected organs.

For liver pathologies, enzymes such as alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) indicate biliary involvement, while aspartate aminotransferase (AST) and alanine aminotransferase (ALT) point to hepatocytes. Conventional markers of hepatic synthetic function-albumin, bilirubin, and international normalized ratio (INR)-correspond quantitatively to the degree of liver compromise. Novel biomarkers aim to improve diagnostic accuracy for liver fibrosis, steatosis, inflammation, and hepato-cellular carcinoma. Emerging non-invasive tools include steatosis and fibrosis score systems, as well as enzyme-linked immunosorbent assays (ELISA) panels that provide serological evidence to complement ultrasound or

elastography imaging techniques in acute and chronic settings.

Kidney function markers such as creatinine levels and the estimated glomerular filtration rate (eGFR) are crucial elements in the assessment and stratification of acute kidney injury (AKI) and chronic kidney disease (CKD) risk, tailored according to various contextual variables that may influence their accuracy and relevance. Although additional markers indicative of tubular damage and injury kinetics play an important role in providing decision support for patients experiencing AKI, especially those who are critically ill, routine assessments of kidney function remain fundamental to guiding the clinical approach during both the acute and chronic phases of kidney diseases. In the context of chronic disease, the use of conventional measures of urinary protein excretion, coupled with semi-quantitative dipstick investigations, proves invaluable in characterizing nephron involvement. This approach aids clinicians in the precise designation of conditions such as diabetic nephropathy, nephrosclerosis, glomerulonephritis, tubulointerstitial disease, and polycystic kidney disease. Additionally, the introduction of novel biomarkers enhances our ability to improve stratification of glomerular involvement, predict tubular repair, monitor kidney transplant success, and differentiate between AKI and prerenal azotemia, leading to better patient outcomes and more informed clinical decisions.

Contents

Chapter - 1

Foundations of Liver and Kidney Biochemistry

A thorough and comprehensive understanding of the intricate biochemical underpinnings associated with liver and kidney disorders is utterly indispensable in nurturing the ongoing evolution of their diagnosis, prevention, and management. These critical organs exhibit considerable metabolic functional divergence and diversity, which serves as the foundational basis for compartmentalizing relevant and pertinent biochemical markers into distinct categories that are characteristic of normal physiological function, function/health-related variants, and disease-related disturbances. Such thoughtful compartmentalization not only bolsters but also substantially fortifies the selection process of both traditional diagnostic methods and emerging biomarkers, thereby significantly improving both diagnostic precision and the discernment of therapeutic endpoints that guide treatment strategies. Normal compartment-specific biochemistry effectively segregates baseline concentrations of liver proteins and associated metabolites that remain largely unaffected by the renal biochemistry compartment yet possess vital pathophysiological relevance to maintaining kidney health; similar compartmentalization efforts likewise pertain specifically to kidney-associated analytes with corresponding hepatic correlates. Clinical

Biochemistry heavily emphasizes the fact that relevant liver biochemistry is not confined solely to the established boundaries of hepatic biological compartmentalization; analytes such as cystatin-C, which is a well-established and valuable renal function index, possess significant diagnostic merit and utility in accurately documenting recipient candidacy for potentially hepatotoxic medications and other treatments. In short, the deep appreciation of core compartment-specific biochemical principles empowers the clinical scientist to expertly and judiciously utilize new solutes, innovative peptides, and diverse biomolecules, either alone or in integrative/indexed fashion, while also exercising diligent forethought in the critical processes of screening, sourcing, testing, selection, and systematic arrangement of conventional biomarkers in clinical practice [1, 2, 3, 4].

Chapter - 2

Traditional Biomarkers in Liver Disease

Traditionally, biochemical markers used in the evaluation of liver disease have relied predominantly on two main strategic approaches. Early assessments aimed to pinpoint baseline enzymes or metabolites whose elevations exhibited strong specificity for the liver and carried significant pathological implications. In instances where such targeted markers were not readily available, the time-course of more generalized markers played a crucial role in guiding the interpretation of liver function and injury. The introduction of new imaging techniques has further enriched our understanding of liver pathophysiology, running in parallel with the evolving landscape of serum biochemistry assessments. This historical context is thereby intertwined with the evaluation of classic hepatic enzymes alongside the characterization of renal markers, which are also relevant in certain contexts. The primary focus, particularly in earlier assessments, has been directed toward enzymes that indicate both hepatocellular injury and cholestatic injury, reflecting the liver's multifaceted role in metabolism and detoxification processes. By concentrating on these relevant markers, healthcare professionals can enhance diagnostic accuracy and address potential liver pathologies before delving into the associated complications stemming from chronic conditions and disease progression. Enzymes that are released into circulation following discharge from the liver-such as Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), and γ-Glutamyl transferase (GGT)-have been localized based on their specific organ densities, and the majority of these enzymes are primarily concentrated within liver tissue, which facilitates their separation in contexts of cholestasis. Moreover, the liver is unique as the sole organ responsible for eliminating the metabolic products arising from the ingestion of alcohol as well as acetaminophen, which positions it at the core of the body's drug detoxification processes. The persistence of circulating enzymes following hepatectomy procedures and the histological identification of both acute and chronic hepatitis in perinatal specimens further underscore the vital importance of liver-derived indices in understanding liver function and injury, reinforcing the notion that biochemical markers and enzymatic profiles are indispensable in the clinical evaluation and management of liver diseases [5, 6, 7, 8, 9].

2.1 Enzymatic Indicators (ALT, AST, ALP, GGT)

An assessment of serum transaminases, alkaline phosphatase, and gamma-glutamyltransferase is of fundamental importance in clinical practice. Alterations in tissue-specific enzymes are indicative of hepatocellular injury and cholestasis. These enzymes are widely available and inexpensive to measure yet require careful interpretation to avoid undue diagnostic uncertainty. Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments.

Elevations of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are indications of hepatocyte damage, whereas serum alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) are markers of cholestasis. ALP and GGT are found in organs other than the liver; therefore, a selective approach ensures clinical relevance. Total LDH or other tissue-specific enzymes are now rarely used, although serum glutamate dehydrogenase activity is valuable when disseminated malignancy or myopathy may lead to misleading interpretation.

Transaminases are enzymes that, during instances of hepatocyte injury, are released into the serum. This process allows for the effective monitoring of the degree of tissue damage that occurs in the liver, and it does so independently of the specific mechanism behind the release of these enzymes. In both alcoholic and nonalcoholic steatosis, it is noteworthy that both transaminase enzymes may initially remain within the reference limits, even when there are noticeable fatty changes present in the liver tissue. This situation serves to highlight the limitations associated with these markers in the early stages of the disease when effective monitoring is most crucial. When it comes to liver cell regeneration, particularly in cases of acute viral hepatitis, there is often a typical transient peak in alanine aminotransferase (ALT) levels that can surpass 1000 U/L. Following this peak, there is usually a decline in ALT levels to a range of 100-200 U/L, which occurs concurrently with an increase in aspartate aminotransferase (AST) levels. This pattern stands in contrast to the scenario observed in paracetamol overdose situations, where ALT levels spike and can directly reflect the degree of tissue damage present at the time of presentation or throughout the patient's stay in intensive care. Other medical conditions, including ischaemia, exposure to various toxins, the presence of malignant tumors, and certain cystic lesions, have the potential to cause significant damage to hepatocytes. In such cases, however, there may be minimal to no significant release of transaminases into the serum. This occurs because the volume of enzymes stored within the hepatocytes and their half-life can be considerable, thereby exceeding the leakage that would typically be expected during moments of cellular damage [6, 10, 11].

Elevation of serum ALP, GGT, 5'-nucleotidase, or a combination confirms cholestatic injury after ruling out adrenaline injections or the acute phase of myocardial infarction. These enzymes do not discriminate between intra- and extrahepatic cholestasis and fail to provide guidance on specific aetiology.

2.2 Synthetic Function Markers (albumin, bilirubin, INR)

Albumin, bilirubin, and the international normalized ratio (INR) serve as critical indicators reflecting the hepatic synthetic capacity, yet it is important to understand that the context of a synthetic-to-function ratio greatly shapes prognostic outcomes more than any individual measure does. Markers indicative of liver injury (which are not detailed here) measure acute damage that has the potential to similarly alter the liver's capacity for biosynthesis, but it is crucial to note that these markers are linked in a time-dependent manner to the progression of the underlying disease. Therefore, synthetic-function parameters serve as significant signals of liver health as the disease progresses from an initial metabolic insult to a stage of irreversible dysfunction. Albumin, which is an abundant plasma protein and possesses an extended half-life, continues to be the primary focus of baseline monitoring in this context. The depletion of other proteins, including transferrin, prealbumin, insulin-like growth factor 1, and antithrombin, occurs earlier in the disease progression but is somewhat compensated by de novo synthesis until the respective messenger RNA (mRNA) species begin to decline significantly. A reduction in albumin levels-whether transient or chronic-resulting from conditions such as nephrosis or protein-losing enteropathy does not inherently suggest liver involvement, as long as the overall clinical status, serum bilirubin levels, and coagulation profiles remain within acceptable ranges; hence, understanding this synthetic-function context is critical for accurate assessments. Furthermore, it is important to recognize that a particular disorder may hinder both the production and the breakdown of albumin, which can lead to the preservation of serum concentrations even in the face of deteriorating hepatic function. Bilirubin also plays a vital role as a key accumulator; moreover, unlike ammonia, the lack of systemic venous sampling can help circumvent diagnostic errors that might arise due to global shunting, particularly when intra-hepatic parenchyma remains intact. The INR follows a similar prioritization in this diagnostic approach. The monitoring of synthetic-function parameters is frequently complemented by dynamic tests that evaluate specific liver capacities; these tests include elastography and targeted serological panels that specifically assess fibrogenesis. Ultimately, the data collected from these assessments guide clinical decision-making regarding the necessity of more invasive imaging techniques or biopsies, ensuring a comprehensive understanding of the liver's functional capacity and overall health status [12, 13, 14, 15, 16, 17, 18].

2.3 Dynamic tests and imaging correlates

Time courses for various biomarkers following liver insult or the presence of neoplasm exhibit significant differences across enzymes, synthetic function indicators, and metabolites, which are critical for understanding the underlying pathophysiology. Consensus in the medical community indicates that enzymes, particularly alanine aminotransferase (ALT), undergo an initial phase of elevation following injury, after which there is typically a resolute return toward baseline levels as the individual enters recovery. In contrast, metabolites such as ammonia and bilirubin tend to accumulate in the system and generally maintain elevated levels for a more extended period, reflecting the ongoing stress on liver function. Imaging techniques play a vital role in assessing gross alterations in liver morphology and perfusion distribution; these methods provide insights that supplemental retrospective biochemical tests often neither distinguish clearly nor quantify adequately. Such correlations are invaluable for diagnosis and the assessment of disease stage progression, as they illustrate a linear relationship between advanced hepatic necrosis and the presence of a neoplastic mass, as well as factors related to mucosal marginability, branching perfusion patterns, and, as the condition deteriorates, a noticeable delay in the return to central perfusion following events like hemothorax. Additionally, the presence of depositional effusions serves as an indicator of portal hypertension and direct vascular obstruction; the inherent non-linearity in these processes makes it challenging to apply clonal detoxification analysis via alternative methodologies. The repair of converted and maturing degradation products, such as keratin (specifically CK18), cholecystokinin, and hepatocyte-fibroblast growth factor, post-damage alongside bile salts following neoplasmic conditions, enables tracing the trajectory through recovery. This tracing allows clinicians to recognize and identify the precursors that may have contributed to the pathologic changes observed in liver tissue during the recovery process. [13, 1, 19, 20, 21]

Chapter - 3

Traditional Biomarkers in Kidney Disease

Acute kidney injury (AKI) and chronic kidney disease (CKD) are two related conditions that together constitute a significant global burden of medical care. These conditions are particularly challenging to diagnose and monitor effectively because not all forms of kidney damage result in elevated levels of standard biomarkers such as serum creatinine and estimated glomerular filtration rate (eGFR). This limitation poses a major obstacle for healthcare professionals striving to identify kidney damage and its implications for patient care. The biochemistry of the kidneys that emerges during periods of injury serves as a practical anchor, effectively linking various disorders to an extensive array of potential modifications in biomarkers. These potential markers span from serum and urinary indicators to the intricate tissue-specific involvement that is typically explored within the realm of omics science. Capturing this complex biochemistry requires a meticulous approach, focusing on early-phase tubular markers of damage. Such markers may include N-acetyl-β-D-glucosaminidase or kidney injury molecule-1 (KIM-1), which represent some of the earliest signs of cellular distress within the kidney's structure. Additionally, it is crucial to consider conceptual markers of functional deterioration that still provide the opportunity for timely therapeutic intervention. The eGFR, while being a foundational metric, is instrumental in dissecting the degree of difference between acute changes and those that are more chronic in nature. Within the context of CKD, these baseline assessments continue to play a pivotal role in guiding the selection of appropriate biomarkers during the risk stratification process. However, the landscape is evolving with the introduction of a fresh category of composite panels designed to improve patient assessment and management. Examples of such composite panels include ViaGraft, which comprises biomarkers like NGAL, cystatin C, and protein-to-creatinine ratio, alongside innovative systems like AKIRisk, i-Monitor, and the KidneyIntelX Index. These panels further delineate the extent of kidney injury that has occurred post-initial insult and highlight the risk of progressive decline that may manifest much later on. This structured approach to monitoring kidney injury stands as a testament to the increasing understanding of renal pathophysiology. This understanding is deeply rooted in high-throughput technologies and comprehensive panel discoveries, which work in tandem to provide effective, non-invasive, and broad hazard assessments. However, even with these advancements, the approach remains inherently centered on maintaining functional connectivity to established physiopathological principles that govern kidney health and disease [22, 23, 24, 25].

3.1 Renal Function Indices (creatinine, eGFR)

Serum creatinine (SCr) serves as a notable and reliable endogenous biomarker for assessing glomerular filtration rate (GFR), and therefore is integral in the evaluation of kidney function. This important substance is produced from the breakdown of phosphocreatine predominantly found in muscle tissue and is excreted mainly through glomerular filtration, exhibiting negligible rates of tubular reabsorption and secretion. Importantly, it's crucial to note that no significant intra- or extra-renal factors influence the generation rate of SCr. As a result, when there is an acute drop in GFR, SCr levels build up progressively, continuously increasing until a new steady state is eventually established. Furthermore, GFR estimation can be achieved by measuring the clearance of creatinine found in urine over a comprehensive 24-hour period. Alternatively, estimation equations (eGFR) that rely on serum creatinine and various parameters, including age, sex, weight, and race, allow for GFR reflection without the necessity of urine collection. However, it is important to recognize that these estimation models often tend to overestimate GFR in elderly individuals or in patients who possess low muscle mass. Additionally, the tubular secretion of creatinine adds another layer of complexity when interpreting SCr levels, particularly because certain medications, such as cimetidine and trimethoprim, inhibit tubular secretion. This can lead to a potential underestimation of true GFR values. During periods of stable conditions, where the GFR remains constant and does not show variability, the absence of dynamic changes in SCr serves as an indication of stable kidney function. Consequently, fluctuations in SCr can provide vital insights into alterations in GFR, especially during the critical hours following the administration of nephrotoxic agents, or while recovering from episodes of acute kidney injury after enduring a protracted phase of elevated SCr levels. In light of these specific clinical scenarios, unique statistical indicators based on the daily trends of SCr and the reported eGFR can greatly enhance the understanding of kidney health and function. These indicators are capable of adding considerable additional value and have the potential to significantly refine the existing clinical workflow, making them indispensable tools in nephrology practice [26, 27, 28, 29, 30, 31].

3.2 Tubular Injury Markers (NAG, KIM-1, NGAL)

Increased urinary β2-microglobulin excretion has been reported as an early marker of tubular injury in diverse clinical settings, consistently preceding the rise in serum creatinine by several days. Urinary β2-microglobulin therefore constitutes a potential biomarker of tubular injury in renal allografts. α-1 Microglobulin excretion is also a sensitive indicator of proximal tubular dysfunction, even in early injury when no histological lesions are detectable, and may be particularly useful for low-gestational-age preterm infants at higher risk of acute kidney injury. Altered plasma or serum levels of this protein can occur in liver disease, HIV infection, and mood disorders, which may affect the urinary specificity and sensitivity of the marker.

Monocyte chemotactic protein-1 (MCP-1) is a potent chemokine produced by kidney cells that mediates acute ischemic and toxic kidney injury. The increase in MCP-1 protein and its mRNA is greater in intrarenal lesions than that of neutrophil gelatinase-associated lipocalin (NGAL). In pre-renal and post-renal injuries, MCP-1 gene expression increases comparatively; uremia alone can induce NGAL but not MCP-1, indicating a relative MCP-1 specificity for acute kidney injury.

Vanin-1 is an epithelial ectoenzyme that responds to oxidative stress and catalyzes the conversion of pantetheine to pantothenic acid and cysteamine. Increased kidney vanin-1 mRNA has been observed in ischemia-reperfusion lesions, and elevated urinary vanin-1 concentrations precede conventional markers in nephrotoxin-induced lesions, suggesting that this protein might serve as an early biomarker of acute kidney injury.

Netrin-1 is found to be expressed in the tubular epithelial cells of normal, healthy kidneys. Following the initiation of extracorporeal circulation, levels of netrin-1 in the body increase rapidly, with concentrations peaking at approximately six hours post-circulation and remaining elevated for as long as 48 hours after the procedure. Furthermore, significantly higher concentrations of urinary netrin-1 are detected in cases of ischemic acute kidney injury, which can be induced by factors such as radiocontrast agents, sepsis, and certain drugs. This pattern indicates that netrin-1 levels rise early following renal injury, suggesting that it may play a crucial role as a universal biomarker for acute kidney injury across various conditions [32, 33, 34].

Alkaline phosphatase and gamma-glutamyl transferase (GGT) are endogenous metalloenzymes found in serum and various organs, including the kidneys. Both have shown efficacy as markers of sepsis-induced acute kidney injury involving tubular injury [35].

3.3 Urinary Biomarkers and Proteinuria Profiles

Qualitative and quantitative urinary protein patterns yield complementary insights into acute or chronic kidney disease [36]. Classical approaches classify proteinuria into pre-renal, renal, and post-renal categories based on appearance during the excretion time course. Semi-quantitative dipstick analysis provides a rapid estimate of proteinuria, but attributes low specificity to individual proteins and may miss early kidney damage in certain contexts [37]. Time-dependent changes in individual protein concentrations and protein ratios have been proposed to distinguish among acute tubular injury, glomerular impairment, and obstructive azotemia. The broad panel of analyzed proteins, however, complicates data interpretations and diagnostic decision-making.

Qualitative and semi-quantitative urine screenings provide critical and valuable insights regarding both the presence or absence of specific proteins within the urine and the overall concentration levels of these proteins as well. These thorough evaluation schemes place a significant emphasis on analyzing both representative small and large molecules, respectively, and these methodologies have been utilized for a remarkable four decades. Consequently, a substantial number of proteins can already be tentatively categorized and assigned to widely known and common disorders based on the previously recognized and established protein patterns. These patterns-considered both qualitatively and semi-quantitatively-have been documented across a broad spectrum of diseases that affect the kidneys, thereby enhancing our understanding and facilitating better diagnostic practices in nephrology. [38, 39, 40]

Chapter - 4

Emerging Biomarkers for Liver Disease

Novel biomarkers emerge with promising diagnostic or prognostic value for liver disease, focusing on fibrosis, inflammation, and metabolism. Fibrosis stage assessment is vital for estimating prognosis and treatment response. Non-invasive alternatives to liver biopsy include elastography-based FibroScan and serological assessment-based Enhanced Liver Fibrosis (ELF). Serum fibrosis panels (AFP, APAP, HMBG-1, K-18) show strong correlations with imaging results, with the ELF panel already established in clinical practice [ref: d9fb75fb-e7db-4fd3-8b45-ea5c31a9fff8ref_authors: Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla ref_year: 2021 ref_id: 4aebfa05-853b-464f-aa91-7d70f5cb6aa3ref_authors: Mohammed Ibn-Mas'ud Danjuma, Jamal Sajid, Haajra Fatima, Abdel-Naser Elzouki ref_year: 2019 ref_id: 6581a7fb-5a1d-406b-ad84-df49faaca2b2

Text: Novel biomarkers emerge with promising diagnostic or prognostic value for liver disease, focusing on fibrosis, inflammation, and metabolism. Fibrosis stage assessment is vital for estimating prognosis and treatment response. Non-invasive alternatives to liver biopsy include

elastography-based FibroScan and serological assessment-based Enhanced Liver Fibrosis (ELF). Serum fibrosis panels (AFP, APAP, HMBG-1, K-18) show strong correlations with imaging results, with the ELF panel already established in clinical practiceref_authors: Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla ref_year: 2021 ref_id: 4aebfa05-853b-464f-aa91-7d70f5cb6aa3ref_authors: Mohammed Ibn-Mas'ud Danjuma, Jamal Sajid, Haajra Fatima, Abdel-Naser Elzouki ref_year: 2019 ref_id: 6581a7fb-5a1d-406b-ad84-df49faaca2b2

Fibrosis scoring is crucial to evaluate chronic liver conditions such as non-alcoholic steatohepatitis (NASH)ref_authors: Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla ref_year: 2021 ref_id: 4aebfa05-853b-464f-aa91-7d70f5cb6aa3ref_authors: Mohammed Ibn-Mas'ud Danjuma, Jamal Sajid, Haajra Fatima, Abdel-Naser Elzouki ref_year: 2019 ref_id: 6581a7fb-5a1d-406b-ad84-df49faaca2b2

Diagnostic/prognostic drug discovery attracts significant attention, and efforts concentrate on steatotic epigenomic influence. The apoptotic and necroptotic cell death marker cytokeratin-18 (CK-18) identifies hepatocyte damage linked to steatogenesis as a prevalent mechanism. M30/M65 panels proffer necrotic/apoptotic assessment without liver specificityref_authors: Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe

Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla ref_year: 2021 ref_id: 4aebfa05-853b-464f-aa91-7d70f5cb6aa3ref_authors: Mohammed Ibn-Mas’ud Danjuma, Jamal Sajid, Haajra Fatima, Abdel-Naser Elzouki ref_year: 2019 ref_id: 6581a7fb-5a1d-406b-ad84-df49faaca2b2

Increased cytokeratins indicate liver damage linked to NASH or hepatocellular carcinoma progression; the associated cell-death marker also manifests in liver cellsref_authors: Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla ref_year: 2021 ref_id: 4aebfa05-853b-464f-aa91-7d70f5cb6aa3ref_authors: Mohammed Ibn-Mas’ud Danjuma, Jamal Sajid, Haajra Fatima, Abdel-Naser Elzouki ref_year: 2019 ref_id: 6581a7fb-5a1d-406b-ad84-df49faaca2b2

Immune platelet activation and aberrant fatty acid integration play crucial roles in underpinning the complexity and severity of liver disease pathogenicity. These elements contribute significantly to various liver conditions that can severely impact health. Some of the key determinants in this phenomenon include Apolipoprotein B (APOB) and Fatty Acid Binding Protein (FABP), which are both essential in the process of sequestering hepatic and circulating fatty acids in the body. The regulation of metabolic feedback mechanisms is a fundamental aspect of understanding and addressing the risk of steatosis, a condition characterized by excessive fat accumulation in the liver. Furthermore, certain components associated with pathogen metagenomes, along with interleukin-7 (IL-7), have been identified as influential agents that modify the risk of liver inflammation and its pathogenic actions. In particular, the immune-regulatory protein Interferon Regulatory Factor 8 (IRF8) emerges as a significant factor that can alter the inflammatory landscape in the liver. Lastly, HNF4A is recognized for its role in indicating and regulating broad steatogenic actions, further linking metabolic pathways with liver health outcomes. Thus, comprehensive research into these various components is essential for elucidating the intricacies of liver disease development and for devising effective therapeutic strategies. These findings bring to light the interconnected nature of immune mechanisms and metabolic processes, which are vital for understanding and addressing the growing challenges associated with liver diseases in contemporary medical science. [41, 42, 43]

4.1 Non-invasive Fibrosis Markers (FibroScan, ELF) and Serum Panels

Non-invasive fibrosis markers and serum panels: Indirect markers measure components not directly involved in the fibrosis process and lack diagnostic accuracy. Direct complex markers measure components of the fibrosis pathway and are often used as panels. The Enhanced Liver Fibrosis panel can be used to avoid liver biopsy in the diagnosis of advanced liver fibrosis in 88% of cases with only 14% incorrectly avoiding biopsy, but figures drop for any fibrosis. APRI and FIB-4 are associated with increased cardiovascular and all-cause mortality, with APRI also linked to diabetes-related death.

In a comprehensive meta-analysis that encompassed 13 distinct sites involving a total of 1134 patients diagnosed with HCV, HBV, or NAFLD, the diagnostic performance of two-dimensional shear wave elastography (2D SWE) for effectively differentiating significant fibrosis categorized as F2, severe fibrosis classified as F3, and cirrhosis has been meticulously illustrated in Table 1. Two-dimensional elastography is notable for its real-time, color-coded mapping capabilities, allowing for an evaluation of tissue heterogeneity alongside the quantification of stiffness values. In contrast, MRI elastography presents a significant advantage by facilitating the assessment of the entire liver organ, thus providing a more comprehensive evaluation compared to the somewhat limited assessments offered by ultrasound elastography or even the more invasive liver biopsy procedures. The generation of continuous mechanical waves is initiated from an active driver located outside the examination room, which then transmits these waves to a passive driver placed on the patient’s body, specifically over the liver, leading to a periodic displacement of the liver tissue. The diagnostic performance of magnetic resonance elastography (MRE) is also thoroughly demonstrated in the same meta-analysis, with results detailed in Table 1. It is critically important to recognize that the parameters measured for liver stiffness can differ across the various techniques utilized, indicating that values are sensitive to the method employed. For example, while transient elastography and MRE rely on distinct underlying mechanics and have differing threshold values when diagnosing cirrhosis, it is crucial to note that both measurement techniques report findings in kilopascals (kPa). Since ultrasound-based elastography often encounters measurement failures in obese patient populations, MRI elastography proves to be particularly advantageous for patients suffering from NAFLD who are also classified as obese. Liver function tests, which include vital parameters such as AST, ALT, GGT, total bilirubin, albumin, PT, and platelet counts, are routinely employed in the management and monitoring of all chronic liver disease cases within outpatient clinic settings. Additionally, noninvasive biomarkers can be conveniently utilized in conjunction with the regular blood draws carried out during these routine appointments. [44, 45, 46]

4.2 Novel Enzymes and Cytokeratins (CK18, M65/M30)

Changes in cellular structure and composition inevitably take place as steatohepatitis progresses further along its complex course. The protein family known as cytokeratins is particularly representative of these significant alterations, and these proteins can fulfil a diverse array of crucial functions. Such functions include providing mechanical support to cells, facilitating important signaling transduction pathways, regulating the assembly and organization of intermediate filament proteins, as well as straining the cellular architecture or localizing specific proteins within the cell itself. Among these, Cytokeratin 18 (CK18) stands out as a prominent cytoskeletal protein that is predominantly found in simple epithelial cells. Under various pathological conditions, CK18 can undergo cleavage, leading to the release of distinct CK18 fragments into the circulation system. Notably, with the rising levels of cleaved CK18-specifically the M30 and CK18-Asp396 fragments-there is a concerning, corresponding aggravation in the severity of steatosis, steatohepatitis, and associated fibrosis. This indicates that monitoring CK18 levels may serve as an important and potentially effective biomarker for assessing the ongoing progression of liver disease in patients, thereby providing critical insights for medical professionals managing these conditions. [47, 48, 49, 50]

4.3 Metabolic and Immunologic Biomarkers (APOB, FABP, HNF4A)

Humans are distinctly predisposed to various metabolic disorders, and the metabolic significance of mammalian fatty-acid-binding proteins (FABPs) remains to be fully elucidated in clinical contexts. Circulating FABPs might play a crucial role in assisting healthcare providers in the process of metabolic-risk stratification for individuals. In a comprehensive population-based study, it was observed that the interindividual levels of circulating FABP1 (L-FABP), FABP4 (aP2), and FABP5 showed a considerable degree of variation and presented a distinct pattern of correlation with several clinical factors as well as body fat distribution-demonstrating a notable tendency towards a prediabetic state. Interestingly, these FABPs were significantly, inversely correlated with renal function, which underscores the importance of renal health as a key determinant that should ideally inform the interpretation of circulating FABP levels within various metabolic settings. While circulating FABP4 emerges as a valuable preclinical indicator of metabolic syndrome within the general population, it is worth noting that FABP5 levels tend to be particularly high in individuals who are affected by hypertriglyceridemia.

Additionally, hepatic steatosis represents a not fully elucidated independent risk factor that has been frequently associated with the pathogenesis of insulin resistance along with the components of metabolic syndrome, notably concerning type 2 diabetes and the risk of atherosclerosis. Liver-FABP (L-FABP) is significantly elevated in patients who are grappling with fibrosis, and it correlates closely with liver histology findings in cases of nonalcoholic steatohepatitis (NASH). Due to its remarkable ability to bind to carboxy-terminal hydrophobic fatty acids-substances that are widely recognized as pivotal in the various scenarios related to hepatic-fibrogenesis pathways-L-FABP may prove to be of great value in monitoring the changes in fatty liver that are relevant to the progression of fibrosis, and hence it can act as an essential indicator of hepatic metabolism-linked cardiometabolic risk. Furthermore, HNF4A (hepatocyte nuclear factor 4 alpha) plays a vital role in orchestrating transcriptional programs that are pivotal for proper hepatic metabolism, and variations within this gene can affect the risk of developing hepatic steatosis and metabolic syndrome, independent of body mass index or obesity metrics. In diabetic subjects, it has been found that certain HNF4A variants correlate with altered levels of metabolic markers that indicate an increased risk of insulin resistance and metabolic syndrome. This suggests that the HNF4A genotype might indeed hold considerable promise as a modifier of metabolic risk in clinical practice. [51, 52, 53, 54, 55, 56, 57]

Chapter - 5

Emerging Biomarkers for Kidney Disease

Biochemical indicators of nephron-specific damage and multiple physiological pathways continue to emerge. An evolving roster of markers compatible with point-of-care platforms provides further opportunities for refinements. Precision indicators of glomerular injury-suPAR and MCP-1-allow better stratification of progression risk and therapeutic monitoring. Markers such as KIM-1, EGF, and cystatin C help pinpoint proximal-tubule involvement and assess tubular health after insult. Composite panels aggregating multiple types of markers further boost diagnostic accuracy for acute kidney injury (AKI) and chronic-kidney-disease (CKD)-progression prediction.

The quantification of serum-creatinine elevation plays a notably significant role as a key indicator of the likelihood of underlying pathophysiological processes that may be present in cases of Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD). This crucial understanding implies that the timely categorization and identification of the various causative factors leading to these conditions remains far more relevant than the act of simply collecting the specimen itself. Moreover, the ongoing development of newer composite panels has the potential to greatly enhance the precision and accuracy of cause-specific stratification within these complex conditions. It is important to note that rises indicative of AKI, which are often observed in serum-creatinine-independent measures, frequently accompany the progression of renal abnormalities. This particular phenomenon is exceedingly crucial as it aids in effectively guiding clinical management strategies. By utilizing such measures, healthcare professionals are empowered to make well-informed decisions regarding patient care, thereby avoiding unnecessary delays that could arise from waiting for a potentially evolving trend in creatinine levels over time. In this context, timely intervention becomes essential in preserving renal function and improving patient outcomes. [58, 59, 25, 23].

Kidney diseases are a significant global health burden that affects all age groups, with increases in prevalence and incidence being observed. Chronic kidney disease (CKD) is often asymptomatic until late stages, when irreversible changes occur. Acute kidney injury (AKI) is also an important cause of morbidity and mortality in hospitalized patients. Emerging evidence points to the potential use of biological specimens in urine, blood, and tissue for the discovery of novel kidney disease biomarkers [1]. Current definitions of CKD, AKI, and other conditions do not incorporate such biomarkers. The discovery of an increasing number of molecules that are potentially useful as biomarkers underlines the need for systematic exploration of these methodologies. Genomic and transcriptomic studies in kidney disease have reported a number of omics signatures defining the condition or its severity, even though the clinical relevance of the identified molecules might still be limited. Urinary biomarkers recognized as clinical standards-including albumin, IGFBP-7, and TIMP-2-have surfaced from genomic and proteomic research. The integration of such knowledge with established pathophysiological mechanisms in kidney disease enables traceable proposals about which signatures will be most relevant both in research and in clinical settings.

Kidney disease, especially chronic kidney disease (CKD), is a worldwide public health burden. Despite advances in our molecular understanding of kidney disease, biomarker discovery and translation for clinical decision-making remain challenging. New biomarkers that complement the recommended criteria for chronic dialysis-haplotype, homocysteine, albuminuria and eGFR<15-could address this gap. An emerging paradigm for biomarker development using multi-omic technologies is indeed producing novel candidate indicators at the genomic, transcriptomic, proteomic, metabolomic and microbiomic levels. Many of these indicators are endorsed by agencies of the United States Government for clinical development. However, analytical validation, clinical utility, incorporation into therapeutic decision-making, and connecting with practical clinical endpoints and cost-effectiveness remain the fundamental hurdles for real-world implementation.

KIDs are evolving, and a natural outcome is that new biological information from the intricate genomics and epigenomics of kidney tissues is yielding clinically useful gene-based indicators. More than 500 potentially clinically useful transcriptomic indicators have been identified in the urine of patients with CKD, and a strategy presently in development will make it possible to screen all 20,000 human protein-coding genes for urine disease-associated patterns. Equally, the world-leading in-depth proteomics of urine and serum by researchers at the University of Kyushu in Japan has identified more than 40 proteomic markers approved by the United States Federal Drug Agency for clinical use and therapeutic monitoring.

Kidney disease represents a leading cause of morbidity and mortality on a global scale, driving a pressing demand for the identification of reliable early biomarkers that accurately detect kidney injury and predict the risk of disease progression, complications, and related mortality [2]. Delays in diagnosis are common even for serious conditions that would benefit from biomarker-supported risk stratification, such as acute kidney injury (AKI), chronic kidney disease (CKD), diabetic kidney disease, and post-transplant complications [3]. Existing clinical indicators frequently fail to provide the robustness or specificity required for optimal decision-making, often leading to initiation of high-stakes trials or nephroprotective interventions in patients who are ultimately found not to be at elevated risk. Consequently, there is an urgent clinical need for quantitative measures that capture the broader pathological landscape governing kidney disease, permit the stratification of high-risk patients from large populations, and correlate with treatment-compatible biological variables to enable accurate monitoring and real-time assessment of therapeutic efficacy.

Genomics and epigenomics together influence the hereditary sequence of the deoxyribonucleic acid (DNA) molecule from which genes are derived. Transcriptomics and non-coding ribonucleic acids (RNAs) explore all transcribed ribonucleic acid (RNA) molecules originating from the genome. Transcriptomic markers were associated with chronic kidney disease in candidate plasma biomarkers [1]. Meanwhile, non-coding-RNA markers may serve diagnostic and prognostic purposes [4]. Proteins constitute the next omics layer and the totality of proteins within a biological sample is termed the proteome. Determining the status of the proteome offers insight into cellular activity and potential disease processes, which is particularly relevant for organ-specific or tissue-specific disorders of the kidneys. Urine peptidomics appears promising as it is non-invasive and renal-affecting pathologies should alter urine composition [5]. Metabolomics monitors metabolites produced by cellular and biological activity yielding functional and pathophysiological information that complements genomic and proteomic knowledge. The midstream urine metabolome appears suitable for profiling kidney activity and injury mechanisms.

Kidney disease represents an enormous social burden. The estimated global incidence of chronic kidney disease (CKD) is about 13% and rising, with more than 850 million people affected. Nearly half of patients with stroke, myocardial infarction, or diabetes also have concomitant CKD. The occurrence of end-stage renal disease (ESRD), commonly requiring dialysis or renal grafting, ranges from 2% to 30% in patients with already diagnosed CKD, while acute kidney injury (AKI) complicates hospitalization in more than 10% and is associated with substantial short- and long-term mortality. Bone and mineral disorders are common in dialysis patients and have been linked to increased cardiovascular risk and mortality. Harbingers of symptom development include estimated glomerular filtration rate (eGFR) trajectory, ACEi and/or ARB onset, and urine albumin/creatinine ratio. At any CKD stage, the presence of diabetes, hypertension, cardiovascular disease (CVD), or other comorbidities contribute to an organized clinical neologism, Beaver Syndrome, denoting chronic disease and a pronounced increase in risk for both patients and the healthcare system [6].

Genomics-the study of the entirety of an organism's genes and interactions-has unveiled new avenues for biomarker discovery in CKD and AKI [7]. Genomic studies can parse risk factors, refine stratification, and highlight targets for therapeutic modulation. The precision of genomic signatures is complemented by epigenomic, transcriptomic, proteomic, and metabolomic signatures, and each layer of study adds complementary information by extracting additional insights or narrowing down unrealized discovery opportunities [8]. Epigenetic interactions represent the principal interface between genetic predisposition and disease evolution across multiple degenerative conditions. Identification of quantifiable mid-stream signatures influencing disease evolution promotes disease management and avoidance of unproductive clinical responses limbic to already EXCESSED patients.

An overview of kidney disease transcriptomes in man and mice. The progressive nature of chronic kidney disease (CKD), along with the high prevalence of diabetic kidney disease, necessitate the search for kidney disease biomarkers. mRNA expression profiling of kidney biopsies can distinguish diabetic from non-diabetic kidney disease. Longitudinal gene expression studies in mice support the accumulation of gene expression changes in kidney and urine RNA, with parallel shifts in CKD-related serum biomarkers indicative of mRNA changes in the protein-coding compartment. Each CKD model supports the identification of an integrated panel of RNA-based biomarkers.

Kidney diseases can be caused by a variety of insults such as hypertension, genetic or metabolic disorders, infections, toxins, ischemia, immunological disorders or allograft rejection. These renal insults may promote the development of chronic kidney disease (CKD), a major health problem affecting ~ 10% of the general population and causing a huge economic and personal burden. In clinical practice, kidney damage is generally detected by changes in serum creatinine and a creatinine-based estimate of the glomerular filtration rate (eGFR), and/or urinary albumin/protein excretion. However, both methods have major limitations, including nonspecificity, substantial variability, and lack of accuracy. A significant increase in serum creatinine concentration indicates that more than 50% of the glomerular function has been lost, a stage of substantial irreversible damage. Albuminuria may represent an early marker of renal injury proceeding a decline in renal function. However, it is not able to distinguish different types of proteinuric kidney disease and has a limited ability in the prediction of disease progression and determination of therapeutic efficacy.

In order to effectively develop personalized medicine for kidney diseases, more accurate biomarkers for use in the clinic are required, as the current markers of kidney damage apply at a later stage of the disease, lack precision, and are not connected to molecular pathophysiology. Analysis of urine peptide content has emerged as a promising area of biomarker discovery. Urinary peptidome analysis allows the detection of short- and long-term physiological or pathological changes occurring within the kidney. Extensive studies of urinary peptidomics in renal patients have indicated that this approach may greatly improve kidney disease management by supporting earlier and more accurate detection, prognostic assessment, and prediction of treatment response. Furthermore, it promises a better understanding of kidney disease pathophysiology and has been proposed as a liquid biopsy to discriminate various types of renal disorders. Considering that proteins are major drug targets, peptidome analysis also allows evaluation of the effects of therapies at the level of protein signaling pathways.

The human gut hosts over a thousand species of microorganisms, which are collectively known as the gut microbiota. These microorganisms play an important role in human metabolism and have been associated with various diseases, including chronic kidney disease (CKD). A pioneering microbiome analysis examined over 200 metagenome-derived microbial species from faecal samples of healthy and CKD-afflicted individuals. In CKD, the abundance of several species (for example, Oscillibacter, Alistipes, and Clostridium) was reduced, while an increase in other species was linked to the elevation of potentially toxic gut-derived metabolites, such as p-cresyl sulphate, indoxyl sulphate, and trimethylamine-N-oxide. The metagenome-derived microbial indicators were associated with kidney-trait-related metabolite levels in serum and urinary creatinine, urine albumin-creatinine ratio, and estimated glomerular filtration rate (eGFR). These biomarker candidates could assist in studying the role of the microbiome in kidney disease and support the development of targeted therapies [9].

The gut microbiome affects CKD through diverse mechanisms. The accumulation of toxic gut-derived microbial metabolites (e.g., p-cresyl sulphate and indoxyl sulphate) results in increased intestinal permeability, systemic inflammation, endothelial dysfunction, insulin resistance, and activation of the renin-angiotensin-aldosterone system, all of which can induce or aggravate CKD. Harmful metabolites from disordered intestinal flora stimulate the autonomic nervous system, creating a vicious cycle within the brain-gut-kidney axis. Transplanting sterile faecal filtrate containing specific bacteria degrades these metabolic wastes and improves renal injury and fibrosis in experimental mice, indicating that targeting particular intestinal flora could represent a therapeutic strategy [10].

Imaging and functional readouts are key additional pillars of kidney disease biomarker discovery and development. Advanced imaging approaches and disease progression modelling strategies extract further prognostic power and enrich kidney disease decision-making beyond measures of structural change. Trajectories of estimated glomerular filtration rate (eGFR) reflect kidney function development rather than snapshot values and better capture the kidney reserve for recovery after acute injury induced by renal transplantation or dialysis, whereas well-designed cohorts can identify early eGFR drop as a risk marker for post-operative acute kidney injury (AKI). With the advent of stage-specific metadata, modelling eGFR slope is now becoming integral to large-scale clinical trials.

Metagenomics has enabled the generation of microbiome-derived features linked to kidney disease risk, along with entry and endpoint indicators formed through the integrated application of cohort-associated machine learning to gut microbial products and activities. Such microbiome-derived functional features now invite interrogation in the context of kidney disease biology. Microbiome configuration potentially contributes to eGFR change after kidney transplantation, while multidimensional microbiome modulation in experimental models can influence acute and chronic kidney disease severity.

Advanced imaging techniques allow non-invasive and systemic evaluation of kidney structure and function, offering important information on nephron loss and other aspects of injury not captured by conventional biomarkers [11]. Such studies measure changes in volume, structure, function, and in some cases, molecular events in the kidneys [12]. X-ray imaging microfil enables 3-μm resolution vascular reconstruction and reveals reduced vascular density after injury. Synchrotron radiation X-ray imaging provides strong penetration, high sensitivity, multi-scale resolution, and low dose for whole organs. High-Resolution

Imaging of Phosphorus enables cross-scale imaging and, supported with virtual histology, contributes to a panoramic 3D kidney pathology map and time-series assessment of injury. Synchrotron radiation-based high-resolution technologies may reveal physiological microstructure and pathophysiological changes, aiding 3D pathology diagnosis and the development of a microstructure atlas for mechanistic research.

Real-time and non-invasive molecular imaging of renal status facilitates understanding of injury and development of therapeutics. Conventional techniques such as glomerular filtration rate measurement, urine analysis, and biopsy provide limited information. Imaging and spatial omics use contrast agents, molecular probes, and tracers to support personalized diagnosis and therapy. Selected molecular probes recently developed for renal applications label early acute kidney injury biomarkers for long-term, real-time kidney imaging and monitoring of injury [13]. Advanced-materials-based imaging is increasingly important for acute injury diagnosis.

eGFR offers a limited overview of renal function, lacking insight into interindividual variability and sensitivity to changes in renal mass [1]. Consequently, attention has shifted towards eGFR trajectories-an analysis of longitudinal eGFR data that captures decline rate and leads to distinct progression patterns. Early-stage pre-clinical chronic kidney disease (CKD) corresponds with preserved reserve-phase function and explosive decline rate, while advanced-stage pre-ESRD CKD shows complete loss of reserve and gradual decline. Reserve-phase eGFR trajectories portend future end-stage renal disease or dialysis [14].

Kidney structures and functions adapt to diverse physiological demands, incorporating volume homeostasis, sodium waste, acid-base control, trace-metal consumption, toxin removal, and urea excretion. The concept of a kidney reserve that embodies the coupling of functional mass to physiological demand serves as a relevant framework beyond eGFR. Despite the well-known role of kidney reserve as a physiological concept regulating vital functions, its operationalization as a quantifiable indicator remains limited.

Urinary biomarkers have provided early and crucial insight into kidney disease that is already being standardized and endorsed by the United States Food and Drug Administration and the European Medicines Agency. Urinary albumin, a normative screening biomarker for chronic kidney disease (CKD) due to its association with glomerular damage, remains a focus of study, as large-scale clinical trials involving more advanced proteomics approaches, such as mass spectrometry, continue to confirm the relationship between multiple proteomic signatures and albumin level. Furthermore, recent advances in genomics and messenger ribonucleic acid (mRNA) expression on well-defined cohorts have affirmed that eGFR (estimated Glomerular Filtration Rate)-long considered the golden standard of kidney function-is actually a composite of multiple independent signals, including several standard and non-standard urinary and serum biomarkers, thereby establishing important new dimensions for biomarker development [1]. The precise influence of these additional markers on the eGFR-to-albumin-risk-index relationship has yet to be delineated.

Albuminuria has long served as an essential urinary biomarker for revealing increased cardiovascular risk in people with diabetes, its association with cardiac events is now well established. Therefore, miniaturized equimolar mass spectrometry (MS) offers a noninvasive method for probing diabetic storage cardiac disease before morphological alterations become clinically apparent. Neutrophil gelatinase-associated lipocalin (NGAL) was among the first urinary biomarkers of plumbism-induced acute kidney injury (AKI) in rats and is now already in clinical use for human AKI diagnosis. Other NGAL-related biosensors seek an upper respiratory infection trigger, whereas vascular endothelial growth factor D-detecting systems indicate cerebral malaria-associated AKI risk. Among others, monocyte chemoattractant protein-1, kidney injury molecule-1, and L-FABP join albumin in predicting renal outcomes. Further biosensors and point-of-care technologies directly address sodium, potassium, or hydrogen ions and achieve promising levels of analytical validation and clinical utility.

Selected biomarkers have received formal endorsement from the United States Food and Drug Administration or European Medicines Agency for estimating the risk of acute or subacute tubular-cell injury following coronary artery surgery with cardiopulmonary bypass, transcatheter aortic valve replacement, cardiac surgery in general, and rhabdomyolysis. Novel long-read and metagenomic sequencing technologies are reshaping microbiome research. Microbiome-derived metabolites and indicated functional products, such as cholesterol and isoprenoids, serve as additional risk factors for cardiovascular disease. The predominance of Bacteroidetes governs the composition of recently developed gene-based, metagenomics-derived, cardiovascular-event-prediction models.

Urinary biomarkers remain the primary investigative target for chronic kidney disease (CKD) non-invasively and without the influence of confounding factors. Albuminuria is the historically most widely studied urinary biomarker, but its association with CKD development and progression is inconsistent. Regulatory bodies endorse peptidomic markers as the first and only kidney-related biomarkers in urine, concurrently with an interest in serum-associated markers [5].

CKD risk increases progressively with serum levels of two peptides-urinary peptide recovery is not directly correlated. The urbanized-to-motorized ratio exhibits an inverse association with eGFR trajectory but does not reflect serological levels. Considered together, these candidates offer added prognostic information complementary to albuminuria and creatinine-based indicators [15].

Before a new biomarker can enter clinical practice, it must undergo analytical and clinical validation and be aligned with patient-care pathways [1]. Analytical validation-ideally conducted under a rigorous quality-management system-demonstrates that the biomarker consistently measures the intended analyte, and includes clarity about storage, transport stability, extraction protocols, matrix effects, splice-variant specificity, and expected measurement ranges [3]. Standardization-both of the biomarker itself and the clinical parameters associated with patient use-facilitates the same tests being performed across laboratories and the ability to contextualize results [16]. Analytical validation and standardization thus contribute to an understanding of how different biomarkers integrate into patient decision-making, paving the way to a comprehensive appraisal of clinical utility.

The clinical utility of a biomarker is supported when population-level evidence shows that its measurement improves decision-making compared with alternative options. This consideration encompasses the performance of existing substitutes-the historical "gold standard," patient-management deviations, diagnostic- and prognostic-testing forecasts, and earlier options for community use-and demand for the new approach. Most broadly, practical adoption of a biomarker depends on its analytical validation, standardization, integration into clinical-decisions frameworks, and demonstrated clinical utility. The transition of biomarkers into real-world utilization faces conventional obstacles: extensive and multiparty engagement is essential for translation to keep pace with their ongoing discovery.

5.1 Analytical Validation and Standardization

Emerging clinical practice guidelines for chronic kidney disease (CKD) recommend periodic screening for individuals at increased risk. Traditional screening relies on standardized measurements of serum creatinine and the calculation of estimated glomerular filtration rate. These tests, although widely used, do not reflect the progressive nature of CKD and, depending on the stage, may not provide sufficient insight concerning prognosis and/or evolving pathophysiology. For the proposed evaluation of mineral and bone disorder (MBD), the Biochemical Society caution that testing of parathyroid hormone (PTH) should only be undertaken in those with renal impairment.

No single biological parameter universally indicates the onset of significant kidney damage, changes in residual or removal capacity, or the evolution of multiple renal pathologies with different prognoses and therapy. The longitudinal, non-invasive, and rapid nature of urine sampling together with the relatively simple analytic procedures commonly involved has stimulated significant research to improve the capacity of urine markers for the detection of acute or chronic renal failure, injury, and specific types of renal disease-such as disorders predominantly affecting the glomerulus or tubules, cyanotic heart disease, obstruction, nephrotoxicity, and so forth [3]. In neonates, immature renal function together with physiological alterations related to development conspires to further complicate the interpretation of standard markers of renal function and injury, necessitating concurrent monitoring of renal blood flow estimation.

A major challenge in biomarker development for kidney diseases concerns their integration in clinical decision-making. Analytical validation establishes precision, accuracy, stability, and reporting limits of biomarkers [3]. Only a limited set of regulatory-cleared serum and urine indicators are currently validated for commercial use. In routine practice, biomarkers should ideally be linked to clinical management and predictive models of disease trajectory. Furthermore, biomarkers need to accommodate accessibility and logistical considerations associated with sample acquisition. Hence, laboratory-developed tests-evaluated by the medical community but with a lower regulatory burden than companion diagnostics-generally remain the most feasible avenue to clinical implementation.

Despite the abundance of kidney-related biomarkers emerging from omics studies, few have completed the validation cycle in fully integrated clinical settings. At present, three urinary readouts-albuminuria, soluble urokinase plasminogen activator receptor, and kidney injury molecule-1-are included in clinical practice guidelines and supported by regulatory endorsement [17]. Regulatory recognition typically requires analytical validation and comprehensive multicenter studies demonstrating clinical utility across diverse populations and settings. In chronic kidney disease, proteomic and transcriptomic descriptions are already being employed to refine risk estimation for these traditional biomarkers and to define high-priority research targets for comprehensive multi-omics [7].

Chronic kidney disease (CKD) is a major public health threat. Many patients do not access standard care. Recurrent measurement of kidney function (e.g., estimated glomerular filtration rate, eGFR) is paramount in the general population. Advanced chronic kidney disease disproportionately affects ethnic minorities. The functional decline of diabetes-induced, autosomal-dominant polycystic kidney disease and immunoglobulin A nephropathy is highly heterogeneous and as high as 20 ml/min/year throughout the spectrum of disease, leading to perplexity in the monitoring of disease progression and foreshadowing eventual end-stage kidney disease [3]. They still stand to benefit from strengthened clinical management.

The discovery of biomarkers that predict both specific kidney conditions and their clinical progression is just as relevant to the pathophysiology of most chronic kidney disease (CKD) subtypes as it is to that of acute kidney injury (AKI) from multiple etiologies, glomerular diseases, and tubulointerstitial injury. The potential for kidney imaging signals or omics-based modalities to become integrated parts of complementary panels is worth mentioning.

For chronic kidney disease (CKD), specific panels of the underexamined urinary peptidome have been suggested that not only capture the greater risk associated with Diabetes Mellitus Type 1 but also reflect stage-specific endpoints [5]. A burgeoning literature on the urinary metabolome of diabetic kidney disease indicates plausible pathways for stage-specific signatures that may already be discernible in the early clinic and require attention [1]. When examining the progression of clinically normal kidneys not yet classified as CKD, the regular decline of estimated glomerular filtration rate (eGFR) trajectories marks another potential point of interest [2].

Chronic kidney disease (CKD) encompasses diverse etiologies, pathogenetic pathways, histological lesions, clinical courses, and prognoses. Because the natural history of CKD and the efficacy of interventions vary markedly among patients, precise prediction of disease courses and outcomes is critical to stratify patients for targeted prevention strategies and clinical trials. Risk stratification based on age, proteinuria, glomerular filtration rate (GFR), and the presence of diabetes and hypertension has proven useful. However, additional biomarkers may further enhance accuracy, particularly in early-stage CKD.

Recent genomic, epigenomic, transcriptomic, and proteomic studies reveal distinct molecular signatures associated with specific CKD subtypes and prognosis. Proteomic classifiers developed to predict deterioration in CKD due to various etiologies hold promise for routine clinical use. Given the need to refine interventions according to underlying biology, efforts are underway to integrate imaging and omics-based biomarkers with protein-based classifiers for comprehensive risk stratification [1, 2, 3].

Acute kidney injury (AKI) is a common complication of hospitalization that can progress to chronic kidney disease (CKD). Hence, identifying patients at risk of developing AKI is crucial. Different underlying mechanisms lead to diverse clinical manifestations of AKI. A number of urinary biomarkers whose levels are altered by these mechanisms have been identified. These biomarkers, along with time-integrated creatinine levels, allow the stratification of patients according to the risk of developing AKI and represent opportunities for preventive therapies and delivery of targeted treatments [18]. The molecular signatures of different AKI etiologies in plasma and urine have been clinically validated, demonstrating the capacity to specify the underlying mechanism early in the time course of AKI [7]. The additional dimensionality provided by these signatures allows complementary stratification based on the risk of progression of AKI and of chronic kidney disease after the resolution of the acute insult. Integrated risk panels that identify early on the population of patients at higher risk of progression are therefore within reach of clinical implementation.

A multi-omics approach highlights signature profiles for risk stratification in predominant kidney diseases. Glomerular diseases and tubulointerstitial injury arise from different types of injury and an integrated approach can combine imaging and multi-omics data. In glomerular diseases, urinary alterations link to disease-specific mechanisms of injury and can inform prognosis, while post-injury eGFR dynamics can reflect renal reserve. In clinically heterogeneous tubulointerstitial damage in diabetes or other metabolic conditions, transcriptomic profiles and microbiome indicators of risk stratification complement imaging and provide stage-specific information. For the predominant diseases, signatures based on multiple layers of information inform diagnosis and severity assessment.

In patients with chronic kidney disease (CKD), the identification of urinary proteomic signatures associated with the various aetiological groups and a prediction model for rapid deterioration of eGFR represent relevant steps towards the integration of non-invasive modalities with clinical information for risk stratification. The inclusion of eGFR trajectories to assess renal reserve underlines the importance of this information in setting prognosis based on factors such as the presence of glomerular injuries linked to immunological dysregulation, with possible integration of other emerging biomarkers such as transcriptomic profiles from kidney biopsy.

Patient privacy is of paramount importance for the value of kidney-related omics information. Although the patient-physician relationship typically remains confidential and stored data are anonymized, this is not necessarily the case for data sharing or use of decentralized processing architectures. Possible invasion of the right to be forgotten, coupled with non-trivial pathogen-microbiome interactions and the increasing use of electronic health records (EHR), further complicate equity in data sharing and its impact on equity in population health [8].

Equity in system access, including hardware availability and Internet coverage, further affects the real-world impact of information generated about kidney disease. Although existing EHRs can support initiative-scale monitoring of omics, use of EHR data from platforms such as the UK Biobank remains concentrated in a few countries, decreasing the benefits of data analysis by local populations [1] and thus the equitable application of any benefit for kidney disease. Similarly, the use of existing omics-based data pools such as the Genomic Data Commons, other portal systems, and repository sites to develop bespoke monitoring systems for specific populations is often not accompanied by sharing of resulting frameworks, further reinforcing inequity.

Patient privacy and data sharing are critical considerations fueling the ethical, legal, and social implications discussion. The rapid developments in genomics, proteomics, and imaging analysis pose challenges regarding patients' rights and the safe and equitable use of generated data. Patients undergoing routine examination may be confronted with unexpected results from genomic and metagenomic sequencing of their urine, blood, or microbiome. Consequently, the de-identified sequencing data produced by kidney disease cases and controls, along with other data generated across the transplantation-specialized Kidney Disease Omics and Transplantation at Washington University in St. Louis and the University of Pennsylvania cohort, should meet the standards set by the Research Data Alliance and be readily accessible to qualified researchers who agree to the sharing and use conditions.

Equity in Access to Biomarker-Based Care requires that validated biomarkers be applicable across diverse populations and care settings. The evidence for some proposed biomarkers of renal function in CKD is not overwhelming, and many studies are limited by small sample sizes and lack of replication. Identification and validation of undiagnosed disease, patient stratification, and monitoring of kidney disease would benefit from robust biomarkers. Multiple genes have been associated with renal diseases, but the utility of many biomarkers remains uncertain, and confirmation in larger, diverse cohorts is needed. It is unlikely that a single biomarker will significantly improve CKD risk prediction beyond current tests; progress will come from combining multiple biomarkers into classifiers that integrate genomic, epigenomic, proteomic, and metabolomic data to improve diagnosis and prognosis. Cost-effectiveness varies by setting, and targeted screening in high-risk groups may be more economical than broad population screening. The use of panels of biomarkers and disease-specific molecular tools could delay renal replacement therapy and reduce overall costs, though careful consideration of the small effect sizes of individual variants is necessary [1].

Future directions for biomarker discovery should prioritize patient-centered value while addressing access and implementation barriers across diverse healthcare settings. Integrative frameworks combining multiple omic domains hold promise yet remain underexplored. Continued attention to longitudinal datasets promises insight into disease trajectories while enhancing individualized assessment of progression and treatment response. Investigations into unobtrusive measurements of real-world function and lifestyle in the ambient environment could further enrich the activity-level perspective.

The complex interplay between genetics, the environment, the microbiome, and their effects on kidney disease can be better defined using analytical protocols that integrate data generated by different biological platforms in a multi-omics strategy. Substantial progress has been made in describing the pathogenesis of kidney disease by linking single-omics-derived signatures with disease outcomes. However, disease biomarker discovery could benefit from integrative multi-omics approaches. Within integrative frameworks, multi-omics signatures can provide mechanistic insight and be expanded to population-wide application through interpersonal or interoperational metagenomic scaling and transformation. These general principles can be applied across all diseases and have the potential to greatly accelerate the discovery of novel kidney disease biomarkers.

Innovative biomarkers that capture the main causes of chronic kidney disease (CKD), acute kidney injury (AKI), and glomerular disease across all tissues must be developed; such biomarkers can add value to eGFR, volumetry, and traditional urine measures, thereby improving the accuracy of risk stratification and therapeutic intervention. Consequently, the quantitative representation of eGFR trajectories and kidney reserve in decision-making pathways may benefit from the incorporation of microbiome-derived indicators, for monitoring treatment response and the disease's natural course.

Technical guidance often indicates the significance of longitudinal cohorts and real-world (RW) data in facilitating clinical readiness of biomarkers, permitting post-approval verification of efficacy across wider cohorts and diverse geographies. Within the kidney field, such data would bolster initial evidence from clinical cohorts for urine and serum biomarkers that predict disease progression across chronic kidney disease (CKD) subtypes; the mechanism of preservation of residual kidney function in type 1 diabetes ([19]); and the risk stratification offered by established, readily obtainable parameters in patients traversing the coronavirus disease 2019 ([20]) continuum, including CKD stage, albuminuria, diabetes type, sex, and age. High ambulatory and nocturnal blood pressure enables the refinement of individualised diabetes-specific risk metrics and strengthens the argument for introduction of a kidney-related end-point through complementary longitudinal pre- and post-RW analysis.

An ideal biomarker set empowers personalized patient management, customizing decision-making for patients at differential risk of disease progression and optimizing therapy. The incisive power of such biomarker tests is particularly evidenced in oncology: these tests stratify cancer patients into populations most likely to respond to new treatments, enable treatment de-escalation among likely non-responders, and facilitate monitoring for emergence of treatment resistance. Similar tools are lacking for common kidney diseases, where timely and accurate risk prediction could revolutionize decision-making and trial design. They are desperately needed to enable therapeutic monitoring by connecting treatment response to clinical endpoints during drug development, thereby improving the chance of success in late-phase trials.

Beyond treatment response prediction, a personalized risk model could utilize pathway-specific biomarker signals to generate individualized estimates of disease progression. Such predictions could support the eventual adaptive use of expensive immunogenic therapy for patients at greatest risk of clinically relevant disease progression. Identification of integrated biomarker panels for common deployment in clinical practice would constitute a crucial step toward enabling personalized nephrology. Such panels would integrate regulatory-endorsed biomarkers with those emerging from the current-wave multi-omic datasets across core nephrology disciplines, including metagenomics-derived signals.

Individual patient-centered value arises from emerging biomarkers that extend clinical reach and improve understanding of disease. Discovery begins with the identification of informative signals that stratify risk or project trajectory. Translational efforts advance commitment to investigational evaluations in clinical settings. Analytical validation establishes retrievable quality metrics and predefined descriptive features applicable beyond original cohorts. Standardization introduces reference materials and distinct protocols for agreement across instruments, sites, and time. Creation of biomarker-based criteria formalizes disease definitions and populations, contrasting against clinical those reliant solely on signs and symptoms, and establishes framework-driving signature panels for a spectrum of unifying indications or agnostic time-series systems. Efforts unify terms regarding disincentives, diluting concern about misalignment between discovery courts and eventual clinic accessibility, while encouraging conceptualization of later-stage panelized drivers representing time-correlated examinations jointly proximal to prescribed therapeutic pathways. The patient-centered nature of discovery-free signal becomes increasingly pivotal within broader value deliberation frameworks. Transport beyond high-resource centers affects equity of access, challenging responses to broad-reaching patterns such as ambient climate influences requiring the natural endorsement of hybrid measures complementing observational approaches.

5.1 Precision Indicators of Glomerular Injury (suPAR, MCP-1)

Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) represent two of the leading causes of morbidity and mortality worldwide. The identification of early glomerular injury and the prediction of its subsequent progression to clinical AKI or CKD remain unmet clinical needs. [60]

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) - suPAR is the circulating form of a membrane-bound glycoprotein named uPAR, a receptor for the urokinase-type plasminogen activator that is found in endothelial and immune cells such as neutrophils, activated T-lymphocytes, and macrophages. Soluble urokinase-type plasminogen activator receptor concentrations significantly increase upon inflammatory stimulation during immune activation and are associated with disease severity in various pathologies and can thus serve as a prognostic marker. Experimental models and clinical studies indicate that elevated suPAR precedes the development of AKI, highlighting its potential utility as a biomarker. A novel automated platform enabling turbidimetric measurement of suPAR in plasma has recently been introduced, with acceptable clinical performance and high throughput capabilities, thus facilitating biomarker development." (Reisinger *et al.*, 2021; Ahmed *et al.*, 2019).

Monocyte Chemoattractant Protein-1 (MCP-1) is a protein with a molecular weight of 8 kDa, belonging to the CC family of chemokines. This family also includes other crucial molecules such as CCL3, CCL4, CCL5, and CCL2, all of which play significant roles in immune responses and inflammation. MCP-1 is secreted by various cell types and serves as a paracrine factor, meaning it acts locally to influence nearby cells. One of its primary functions is to trigger the chemotaxis of monocytes, guiding them to sites of inflammation or injury. This process is particularly important in the context of the pathogenesis of various human diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD). Research has shown that elevated levels of MCP-1 can be detected in the plasma and urine of patients, and these increased levels are correlated with renal dysfunction across a range of different pathologies. This observation suggests that MCP-1 could have valuable diagnostic and prognostic implications. Specifically, it may serve as a potential marker for identifying isolated glomerular injury, as well as for monitoring the progression toward conditions like AKI or CKD. As a key mediator in the inflammatory response, understanding the role of MCP-1 could lead to better therapeutic strategies for managing kidney diseases. [61, 62, 63]

5.2 Proximal Tubule and Tubular Health Markers (KIM-1, EGF, CysC)

Kidney injury molecule-1 (KIM-1) and epidermal growth factor (EGF) are promising urinary biomarkers for assessing acute kidney injury (AKI) severity. KIM-1 is a type I membrane glycoprotein that is normally undetectable in urine but is highly upregulated in proximal tubular epithelial cells in response to injury. The KIM-1 mRNA level peaks at 24 hours after AKI induction, and spot urinary KIM-1 protein concentration is a reliable predictor of necrotic tubular injury [64].

EGF is a potent mitogen for tubular epithelial cells and is known to promote recovery after AKI. Urinary EGF levels are positively correlated with histological injury scores and nephron counts and inversely correlated with the number of KIM-1-positive tubules early after cisplatin treatment. Measurements of both KIM-1 and EGF at 24 hours after AKI induction provide valuable information on the degree of injury and recovery potential.

Cystatin C (CysC) is recognized as another significant urinary marker that indicates proximal tubular injury within the kidney. In contrast to KIM-1 and EGF, which serve similar purposes, CysC is notably abundant in the urine of healthy individuals, thereby somewhat limiting its broader applicability in clinical settings. However, it is important to note that elevated levels of urinary CysC are positively correlated with serum creatinine levels and the creatinine-based estimated glomerular filtration rate (eGFR), which are critical indicators of kidney function. By emphasizing additional urinary biomarkers that provide insights into the severity of acute kidney injury (AKI) and the overall health of the tubular structures, these research studies contribute valuable information that aids in refining and enhancing the selection of monitoring parameters used in renal diagnostics and assessments. [65, 66, 67, 68]

5.3 Composite Biomarker Panels for AKI and CKD Progression

Composite biomarker panels have the potential to substantially and significantly enhance diagnostic confidence when it comes to assessing acute kidney injury (AKI) and the progression of chronic kidney disease (CKD).

This improvement is crucial, as it allows for the implementation of timelier and more targeted clinical interventions, which are essential for better patient outcomes. While individual biomarkers provide valuable insights into renal involvement, their information is often limited, highlighting the urgent necessity for a more comprehensive and integrative approach to kidney health assessment. By utilizing multi-analyte combinations, healthcare providers can markedly increase diagnostic accuracy when compared to traditional clinical criteria or single biomarkers alone. In fact, this strategy can lead to a significant shift in management practices towards a more kidney-centric treatment strategy, which is fundamentally more aligned with the specific needs of patients with kidney-related issues. To illustrate, the combinations of urinary neutrophil gelatinase-associated lipocalin (NGAL) with urine protein-to-creatinine ratio, alongside serum creatinine, or alternatively serum creatinine, urine NGAL, and cystatin-C, represent exemplary panels that provide considerable clinical benefits and improvements in diagnostic understanding. In the context of chronic kidney disease (CKD) evaluation, the urinary albumin-to-creatinine ratio (ACR) remains the simplest and most widely adopted marker in clinical practice, owing to its ease of use and interpretability. However, it is essential to recognize that urine ACR alone remains insufficient for thorough risk stratification, particularly notable in the early stages of diabetic nephropathy, wherein precise monitoring is critical. As a response to this limitation, various combinations of biomarkers, such as albumin, matrix metalloproteinase-9 (MMP-9), kidney injury molecule-1 (KIM-1), in conjunction with other indicators, have been thoughtfully proposed to complement urine ACR. This approach aims to enhance predictive accuracy and provide a more robust framework for assessing kidney health, ultimately supporting improved clinical decision-making and better patient management over time. [35, 69, 70, 71, 72, 73]

Chapter - 6

Omics and Digital Biochemistry in Hepatorenal Diagnostics

Understanding the liver and the kidney at the level of proteins, metabolites, and genes (‘omics’) as well as through digital tools can help to improve diagnostic accuracy and predictive ability. High-throughput methods generate massive amounts of data suitable for recognizing biomarkers that remain relevant in the clinical workflow, and at least one group has identified multiple candidate biomarkers of kidney and liver damage [74]. Along the translational path from bench to bedside, prioritization based on genetic variants linked to disease-risk pathways and individual profiles can further refine biomarker selection [58]. Subsequently, computational approaches capitalize on widening clinical databases and machine-learning platforms to discover patterns that can guide clinical decision-making.

High-throughput proteomics is a powerful and innovative technology that can effectively probe and analyze tissue proteomes or serum and plasma proteomes, which aids in helping to define and understand the specific state of various tissues or organs. For instance, in the critical case of kidney damage, a collection of potential translational tissue markers has been proposed and put forward, yet it is important to note that validation according to the STARD criteria stands as a prerequisite for application in the clinical diagnostics arena. This validation is key to establishing trust in the findings. Similarly, high-throughput metabolomics studies have identified numerous candidates that are associated with liver, kidney, drug-induced nephrotoxicity, and acute-kidney-injury damage pathways. However, functional validation in the respective organ or tissue remains essential to draw clear mechanistic conclusions, ensuring robust and qualitatively credible clinical diagnostic applicability. The application of mass-spectrometry-based approaches coupled with untargeted analysis has successfully accentuated and highlighted selected alterations observed in nephrectomy studies that utilize pre-clinical mouse models. This innovative methodology is paving the way for prospective biomarker identification, allowing researchers to explore and evaluate the intricacies of these biological systems in greater depth. [75, 76, 77]

6.1 Proteomics and Metabolomics in Liver/Kidney Disease

Discovery pipelines based on proteomics and metabolomics hold potential for biomarker identification in liver and kidney disorders. Yet barriers remain, including complex data management, differential expression uncertainty amid clinical heterogeneity, and identification of serum-peptide signatures from global profiles [78].

Proteomic exploration starts with mass-spectrometric analysis of plasma/serum or urine followed by statistical evaluation of abundance deviations pertaining to specific conditions. Heuristic models then associate biomarkers with disease processes, complemented by pathway analysis to elucid pathophysiology-data infusion from conventional biomarker ontologies enhances the process [79]. Insights stem from combinatorial regulation understanding and genomic variance acknowledgment that informs biomarker transition likelihood [58].

Beginning with serum-plasma and urine-highly evolved biological fluids that contain a wealth of knowledge-proteomic studies encounter significant challenges in translation; it became crucial to have national renal-pathology datasets and careful scrutiny of proteomic artifacts as necessary precursors to progress. [80, 81, 82]

6.2 Genomics-Informed Biomarker Discovery

Genomic markers have emerged in clinical nephrology and hepatology alongside established biochemical and histologic indicators. Such markers act as pharmacogenomic signatures, providing stratification of disease and therapeutic response within renal or hepatic disorders. Parallel investigative efforts in nephron filtration and hepatic drug metabolism provide complementary opportunities to evaluate omnigenic biomarker panels permeating sequence variation and gene expression across multiple tissue types [1].

Genetic variants significantly influence a multitude of coordinated biochemical processes that shape both normal physiological states and various disease conditions. As a result, the components selected for inclusion in specialized panels, which are deemed important for understanding mechanisms, inherently preserve a wealth of information that transcends the relevance of individual genetic markers. By specifically targeting gene variants that signal the regulatory dosage of the incorporated genes, we can refine our consideration of analytes towards those transcriptionally linked biomarkers that are situated both upstream and downstream, which respond dynamically to biologic treatments. These principles provide a solid foundation for the construction of comprehensive biomarker panels that respect the complexities of genomic structure and the variations found within sequences. Key indicators, both extracellular and intracellular, of nephron filtration capacity, can provide insights into restoration potential and the processes involved in patching phagocytosis. These factors collectively represent candidate proximal tubule markers that are invaluable in identifying the location of chronic injury, assessing the risks associated with subsequent procedures, and evaluating the healing process that follows episodes of acute kidney injury. [58, 83, 84, 85]

6.3 Artificial Intelligence and Biomarker Pattern Recognition

Artificial Intelligence holds great promise for medical applications such as advanced imaging techniques and comprehensive patient records management, yet it has yet to reach its full potential in the crucial area of biomarker discovery. Decision support tools that effectively leverage biomarkers alongside a multitude of other clinical data can significantly aid nephrology diagnostics, offering interpretable guidance that may lead to better outcomes, but these tools require meticulous model validation and thoughtful integration into existing clinical workflows to be effective. Artificial Intelligence (AI) exploits sophisticated algorithms capable of processing vast amounts of data and uncovering intricate patterns that are often hidden from human analysts in traditional healthcare settings. While clinical adoption of AI technology lags behind high-profile fields such as radiology, where visual data capture is relatively straightforward and the numerical data derived from imaging studies seamlessly drive advanced algorithms, other medical fields are increasingly demonstrating AI's vast promise despite their inherent complexities. In the field of nephrology, AI plays a vital role in assisting with the early detection of renal diseases, guiding the management of chronic illnesses, and facilitating precise risk stratification for at-risk patients. Although chemical tests still remain the gold standard in guiding diagnostic pathways, they tend to be subjective and can be affected by variable laboratory conditions, which introduces a level of inconsistency in results. Well-designed decision-support systems can identify abnormalities in kidney function, evaluate renal involvement efficiently, and recommend timely interventions across both acute and chronic contexts. Integrating biomarkers with these decision-support systems greatly enhances the clinical role that biomarkers can play in renal diagnostics, providing deeper insights into patient conditions. Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) affect millions of individuals around the globe, yet biomarker-guided diagnostics for these pervasive conditions present significant challenges. Composite panels that combine established and novel urinary markers with relevant clinical and laboratory variables effectively enhance precision in identifying appropriate intervention strategies. Human-centered frameworks are essential as they align model formulation with pressing clinical questions, aiming not just to identify affected patients but to guide meaningful action based on the insights gained. Capturing user input from physicians not only drives medically relevant model refinements but also strengthens the efficacy of the AI tools. Such frameworks illustrate how Artificial Intelligence can augment the interpretation of biomarkers with comprehensive Patient Reader factors, thereby complicating the detection of kidney-related issues and ultimately contributing to improved patient care. [86, 87, 88, 89, 90, 91]

Chapter - 7

Clinical Applications and Case-Based Reasoning

Diagnostic reasoning is a linchpin linking laboratory and clinical domains. Traditionally, it has centered on findings at the medical examination and the formulation of differential diagnoses. A case-based approach has been proposed to convey discrete sets of central concepts and their interactions for a given clinical picture [1]. The evolution of biomarkers for liver and kidney disorders affords opportunities for similar reasoning in the selection, interpretation, and monitoring of laboratory investigations.

Pathways are readily available for a range of both liver and kidney disorders, and each provides various aspects essential for completeness and the clinical resolution of the conditions being treated (see Figures 1 and 2 for reference). The concurrence of multiple liver-biliary tract affections, which includes chronic viral hepatitis, steatosis, or steatohepatitis, is thoroughly addressed in the respective algorithms designed for these disorders. Furthermore, the independent tracing of both clearance and formation, as well as the pre-post-glomerular phases of renal involvement, enables precise treatment adjustments to be made. These adjustments are essential and take into account various factors, including the underlying etiological causes, prognostic indicators, and necessary therapeutic considerations to ensure optimal patient care. [92, 93, 94]

7.1 Diagnostic Algorithms in Hepatic Diseases

Hepatitis remains a significant and ongoing global health threat that affects millions of individuals each year, resulting in an alarming total of over 1.34 million deaths annually. This staggering number of fatalities surpasses that of more well-known diseases like HIV and malaria combined, underscoring the dire need for greater awareness and proactive health measures. Despite its severe impact, hepatitis is often underdiagnosed and inadequately treated, leaving many individuals vulnerable. The successful implementation of consistent and systematic diagnostic approaches has proven particularly challenging due to the variously complex and diverse pathogen-induced hepatic lesions that can manifest, along with substantial interferences in biochemical assessments. A practical stepwise algorithm has emerged, which uncloisters both classical and non-invasive tests as well as imaging techniques within clinical pathways, and this has demonstrated enhanced capabilities in case-finding and intervention audits across multiple countries. The principal route of transmission for hepatitis viruses is well recognized, and early signs of infection are unearthed through a combination of traditional and modern methods. Furthermore, constraints related to hepatitis are nominal in many regions, and the risks of infection from prevalent pathogens such as Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Hepatitis E Virus (HEV), as well as emerging pathogens like D, G, and TTV, which are not immunized against, can be detected with improved diagnostics. Cross-sectional serology and targeted molecular investigations are now available as deployable confirmatory assays, allowing healthcare providers to accurately identify and monitor these infections. Hepatotropic viruses serve as exogenous infectious organisms, and they are primarily responsible for causing significant liver damage in affected individuals. The risk of progression to chronic infection is dependent on the specific pathogen; for example, the risk is estimated at an alarming 90% for individuals who acquire HBV perinatally, a similar pattern is observed for HCV and HEV among patients who are immunosuppressed. As a result, misapprehensions regarding the underlying paradigms of transmission have far-reaching consequences, impairing both informal assessments of infection risks following diagnostic tests and evaluations of where and in whom to seek empirical treatment effectively. Automation technology for the detailed examination of the crown is often employed; however, existing practices frequently lack the opportunity to thoroughly connect nodular advancements with the pathogenesis of either viral or paraneoplastic genesis. Such automation underscores the importance of focusing on imaging techniques that draw correlations between neoplasia-induced rising aminotransferase trends and the degree of cellular polymorphism that is ascertainable through analysis of cell and nucleous size via electrophoresis. In conclusion, addressing these challenges through enhanced diagnostic strategies and increasing awareness about hepatitis is crucial for better patient outcomes. [13, 95, 96, 97]

7.2 Renal Diagnostic Pathways in Acute and Chronic Settings

The ubiquitous nature of albumin in clinical laboratories makes it easy to overlook its limitations as a post-hepatic damage biomarker. Typically, acute liver injuries correlate with albumin levels while chronic conditions follow a proportional model. The preceding discussion on traditional hepatic markers clarifies cases where ALT elevation cannot be relied upon, notably acute hepatitis, alcoholic injury, and certain drug-induced events. In these instances, monitoring creatinine serves as a non-hepatic alternative; ironically, it is also a pre-hepatic marker. Nevertheless, more robust options exist for crafting a differential diagnosis at such pathways [98].

All-faction equations assume randomness in albumin-liveliness interactions. Thus, if live salvage is anticipated, timely explication of hepatic furnish stock sheds light on overall vitality. The international community largely favors prothrombin time, supplemented elsewhere by factor V or very-late-for-factor, as the central metric. Thrombin boosts fibrinogen until FDP levels peak around 72 hours. Between initial injury and hemostasis thresholds (6-7 days), factor VII potentially remains critical where extrinsic routes exceed intrinsic cascades, especially in rodent hemostasis transients. Up-to-date consideration of albumin also highlights prior paracetamol damage and National Institute of Health standards full-liver salvage probabilities of under 16%.

Ultimately, a sufficient array of factors can effectively lower the standard consumption of probe resources without compromising their overall essentiality. Each additional probe tends to expand the probabilistic margin, subsequently moving tangible possibilities from one specific protocol route to another-thereby facilitating a deeper comprehension of all the underlying intricacies. This understanding becomes particularly crucial when principal avenues maintain their utility, hence entrenching the protocol outlines that were established earlier based on first principles. As a result, simpler scaffold representations can significantly enhance automatic comprehension-efficiently translating various inputs through a freestanding layout that emerges directly from many different instruments. This includes traditional compartments, the necessary storage for building permits, the temporary organ stopover processes, and the expansive broadband routine, all of which contribute to a cohesive understanding of the overall structure. Through these effective scaffolds, biomarker parameters can shift rapidly and seamlessly. Main response matrix data is merely converted into depacked phases, which subsequently allow for a thorough disambiguation of all remodeled reflective occurrences that are pertinent to wider operative spans which pervade every possible stance that might be encountered. This enables a clearer insight into the interrelations and dependencies that exist within the protocols, ensuring a more comprehensive grasp of the entire operational landscape [99, 100, 101, 102].

Chapter - 8

Analytical Considerations and Laboratory Implementation

Biomarkers comprise an exceptionally remarkable class of medical and physiological discoveries, functioning as measurable signals found within a broad spectrum of biological systems. These biomarkers hugely facilitate clinical investigation, diagnosis, prognosis, therapeutic monitoring, treatment efficacy evaluation, and disease prevention at the molecular level, playing an essential role in modern medicine. The liver and kidneys operate homeostatically to achieve a delicate balance of biomolecules as well as foreign substances that are critically important to human survival. A considerable number of liver and kidney biomarkers are considered conventional due to their extensive clinical acceptance, making them vital tools in medical practice. Currently, patient stratification through serum or urine biomarkers, along with biological causality established based on genomic or transcriptomic factors, represent two major additional strategies designed to support clinical decision-making specifically in the context of the liver and kidney. The recent emphasis on the biomarkers that potentially modify existing nephrology practices stems from their capability of creating a widespread impact across various clinical settings. In fact, academic researchers and industrial scientists, along with oversight agencies and clinical expert panels, all recognize the transformative social and economic relevance that kidney- and liver-associated biomarkers bring to the field of medicine. The continuous exploration and validation of these biomarkers promise to enhance diagnostic accuracy, improve patient outcomes, and facilitate personalized treatment approaches in both nephrology and hepatology. [1, 103, 104, 6, 105, 106, 107]

8.1 Assay Selection, Validation, and Standardization

Traditional biomarkers of liver and kidney disease remain crucial for clinical interpretation [108]. Reliable documentation of their meaning is important for informed assay selection. A proper biochemical foundation ensures proficiency when considering traditional indicators and the emerging biomarkers gaining significant traction for diagnostic, prognostic, and therapeutic decision-making.

The liver is central to mammalian biochemistry; its metabolic compartmentalization provides a framework to grasp how various conditions affect hepatic function and how these, in turn, influence laboratory tests. Afterflow from the liver strongly influences plasma analyte concentrations, especially enzymes, influencing the selection of markers [1].

The kidneys intimately regulate plasmatic homeostasis of multiple solutes, the misregulation of which drives widespread physiological disturbances. Fundamentals such as glomerular filtration and tubular reabsorption guide the interpretation of renal function indices and tubular injury markers. Concentration determinations complete the overview by incorporating comprehensive kidney function and enabling the clarification of pre-renal, renal, and post-renal causes even in the absence of damaging pathologies.

Systematic review and comprehensive integration of biomarker pathways confirm significant advances that greatly enhance diagnostics for both liver and kidney conditions, ultimately impacting patient stratification along with therapy selection processes. The timely identification and accurate prognostication of hepatic non-alcoholic steatohepatitis, along with potential liver transplant rejection, have demonstrated that informed recognition of diabetic kidney disease and the capacity for tubular repair benefit tremendously from the utilization of innovative diagnostic tools. Enabling these impressive developments is a robust and established understanding of classical markers that expertly anchor and guide biomarker selection, even in the face of a continuous and permanent inflow of newly proposed alternatives. The extensive knowledge of established tests continues to remain the gold standard against which all cutting-edge candidates are rigorously measured and assessed. [109, 110, 111]

8.2 Quality Control, Reference Intervals, and Population Variability

Reference data for clinical laboratory tests, comprising values within a specified range obtained from a defined population, are generally referred to as reference intervals. The requirements of these intervals differ depending on the specific area of application and laboratory practice, but bound values are generally constants for any particular laboratory. Consequently, the definition of such reference intervals, the population samples used to establish them, and the adjustments made therein for variations according to social factors of the population form the foundations of good laboratory practice and are fundamental to the work of any clinical chemistry laboratory. To this end, the very establishment of individual reference intervals begins with the construction of a valid definition of the population sample, which entails particular consideration of a variety of factors: age, sex, socioeconomic (SES) state, ethnic group, and geographical delineation [112].

Biochemical tests are among the most often requested and employed in laboratories worldwide. Laboratory data can even contrast apparently normal clinical symptoms, where reference intervals form an often vital basis for data interpretation. Monitoring the concentration of specific markers also forms an important aspect of the practice of clinical biochemistry, where the population samples set out above collectively remain crucial to the establishment of individual reference intervals [113].

Population-wide differences in the distribution of biomarker levels have been thoroughly documented across numerous hormones. Reports indicate that these variations primarily stem from differences in liver metabolism and transport, kidney excretion, as well as other contributing factors that encompass both genetic heritage and a range of environmental influences. An extensive and comprehensive study analyzing several hundred population-wide extracts has yielded insights into consistent variations in the value distribution of approximately forty key biomarkers when contrasted across entire populations. Furthermore, this research has significantly contributed valuable information that indicates which biomarkers are likely to be mutually correlated across different analytical approaches, enhancing our understanding of biomarker networks and their interactions within the broader context of public health. [114, 115, 116, 117, 118]

8.3 Cost-effectiveness and Turnaround Time in Biochemical Diagnostics

Cost-effectiveness and turnaround time represent two key parameters that must be carefully considered when planning for the introduction of new routine biochemical parameters. It is essential to strengthen existing internal processes within the laboratory and to establish stable, reliable, and validated new determinations, all while minimizing marginal costs. These enhancements not only improve the quality of laboratory service but also contribute to overall profitability. The advent of high-throughput platforms that allow for the simultaneous measurement of many analytes plays a considerable role in achieving this important goal of efficiency and effectiveness in laboratory operations. Beyond these technical and operational considerations, the analysis of cost-effectiveness extends comprehensively to the introduction of new routine biochemical parameters. A major and critical part of this evaluation centers around the added therapeutic impact of results obtained through these biomarkers. This is crucial since the collection and processing of these additional results may incur significant costs without necessarily leading to a meaningful improvement in clinical management practices. Furthermore, the underlying time constraints in the healthcare environment make the timely receipt of biochemical results an indispensable element of laboratory services. Continuous efforts are made to shorten both preanalytical and analytical delays while ensuring that accuracy is not compromised in the process. The additional costs linked to providing a prompter service are often meticulously evaluated, and the term cost-effectiveness is frequently applied to such analyses to underpin the economic aspects of these decisions. In light of the various cost-effectiveness considerations, a frequent compromise is observed between turnaround time and analytical reliability. This becomes especially evident in lengthy evaluations where time pressures and reliability factors intersect. In this context, precision, which indicates the degree of agreement between multiple independent measurements of the same analyte, represents a critical property that characterizes the overall quality of diagnostic assays. Measures of precision, therefore, do not merely serve as statistical parameters; they provide profound insight into the level of confidence practitioners may have regarding the tissue of origin of samples, particularly in applications such as cytokeratin measurements, which are vital in diagnostic pathology [119, 1, 120, 121, 122, 123].

Chapter - 9

Conclusion

Novel biomarkers continue to reshape liver and kidney diagnostics by refining disease localization, augmenting injury characterization, and improving patient stratification for both therapeutic and prognostic purposes. Emerging markers clarify the nexus between glomerular health and systemic disease, localize proximal tubular injuries untraceable by conventional indicators, enhance decision thresholds for acute and chronic disease evolution, and distinguish acute kidney injury from chronic kidney disease at the later stages of illness.

Integrated biomarker panels boost diagnostic confidence and streamline management, with some combinations guiding clinical choices across the kidney disease spectrum. Established markers, such as serum creatinine and estimated glomerular filtration rate, remain relevant in biomarker-driven pipelines at initial diagnosis, serving as vital context for multiple other indicators and patient clinical histories. The multifaceted role of biomarkers in kidney pathology reflects their centrality to ongoing discovery and development efforts.

The current epoch of digital biochemistry, a fascinating field characterized by the integration of proteomic, metabolomic, genomic, and artificial intelligence technologies, holds promising potential for further advancements in liver and kidney diagnostics. The application of sophisticated computational techniques greatly facilitates the enrichment of clinical laboratories with high-throughput omics data, which in turn enables the identification of complex and biochemically relevant patterns. These patterns are essential as they directly inform biomarkers that are aligned with the uncertainties faced by patients. Additionally, the progress observed in the science of biomarkers continues to evolve in tandem with these innovative computer-based approaches. The diagnostic accuracies achieved, along with enhanced patient stratifications and improved therapeutic monitoring capabilities provided by these evolving biomarkers, collectively reinforce the pivotal role that biochemistry plays in understanding hepatic and renal pathology. This underscores the ongoing and growing needs for continual discovery and deep exploration in this vital area of medical science.

References

1. K. Sumanth Nallagangula, K. N. Shashidhar, V. Lakshmaiah, and undefined Muninarayana, "Evolution of proteomic biomarker for chronic liver disease: Promise into reality," 2018. ncbi.nlm.nih.gov
2. L. Bar-Peled and N. Kory, "Principles and functions of metabolic compartmentalization," Nature metabolism, 2022. nih.gov
3. R P. Cunningham and N. Porat-Shliom, "Liver zonation-revisiting old questions with new technologies," Frontiers in physiology, 2021. frontiersin.org
4. N. Porat-Shliom, "Compartmentalization, cooperation, and communication: The 3Cs of Hepatocyte zonation," Current opinion in cell biology, 2024. sciencedirect.com
5. J. R. Morling and I. Neil Guha, "Biomarkers of liver fibrosis," 1970. [PDF]
6. S. S. Tamber, P. Bansal, S. Sharma, R. B. Singh, "Biomarkers of liver diseases," Molecular Biology, vol. 2023, Springer. [HTML]
7. A. R. Guerra-Ruiz, G. Casals, P. Iruzubieta, *et al.*, "Biochemical assessment of metabolic associated fatty liver disease," *Medicina de …*, 2021. degruyterbrill.com
8. MA Kalas, L. Chavez, and M. Leon, "Abnormal liver enzymes: A review for clinicians," *Journal of Hepatology*, vol. XX, no. XX, pp. XX-XX, 2021.

nih.gov

9. M. E. Rinella, B. A. Neuschwander-Tetri, M. S. Siddiqui, *et al*., "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease," Hepatology, vol. 78, no. 3, pp. 1234-1249, 2023. nih.gov
10. P. Jain, A. K. Batta, and P. Singh, "Comparative study of serum levels of gamma-glutamyl transferase, Aspartate aminotransferase (AST), Alanine Transaminase (ALT), AST: ALT, and bilirubin in patients …," Indian Journal of Medical Biochemistry, 2023. ijmb.in
11. M. Jasiewicz, M. Siedlaczek, M. Kasprzak, "Elevated serum transaminases in patients with acute coronary syndromes: Do we need a revision of exclusion criteria for clinical trials?" Cardiology, 2023. viamedica.pl
12. S. A. Azer and R. Hasanato, "Use of bile acids as potential markers of liver dysfunction in humans: A systematic review," 2021. ncbi.nlm.nih.gov
13. R. Teschke, A. Eickhoff, A. C. Brown, M. G. Neuman *et al*., "Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support," 2019. ncbi.nlm.nih.gov
14. P. Ge, H. Yang, J. Lu, W. Liao *et al*., "Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage," 2016. ncbi.nlm.nih.gov
15. M. Fodor, A. Woerdehoff, W. Peter, H. Esser, "... of relevance and predictive value of parameters indicating

early graft dysfunction in liver transplantation: AST is a weak, but bilirubin and INR strong predictors of ...," Frontiers in ..., vol. 2021. frontiersin.org

16. B. Demirors, R. Shekouhi, P. B. Jimenez, "Redefining the albumin-bilirubin score: Predictive modeling and multidimensional integration in liver and systemic disease," World Journal of …, 2025. nih.gov
17. K. Kajal, V. Ganesh, and S. Sethi, "Physiological role of liver and interpreting liver function tests," in *Operative Anesthetic Management in Liver*, 2023, Springer. [HTML]
18. A. Sonsuz and O. K. Bakkaloglu, "Biomarkers in Liver Disease," Biomarkers in Medicine, 2022. [HTML]
19. M. Villanueva-Paz, L. Morán, N. López-Alcántara, *et al.*, "Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice," Antioxidants, 2021. mdpi.com
20. Y. Bao, M. Phan, J. Zhu, X. Ma, J. E. Manautou, "Alterations of Cytochrome P450-Mediated Drug Metabolism during Liver Repair and Regeneration after Acetaminophen-Induced Liver Injury in Mice," *Drug Metabolism and Disposition*, vol. 50, no. 12, pp. 1234-1245, 2022. nih.gov
21. L. Yu, M. Yang, M. Cheng, L. Fan, X. Wang, T. Xu, "Associations between urinary phthalate metabolite concentrations and markers of liver injury in the US adult population," *Environment International*, vol. 147, 2021. sciencedirect.com
22. I. Lousa, F. Reis, I. Beirão, R. Alves *et al.*, "New

Potential Biomarkers for Chronic Kidney Disease Management-A Review of the Literature," 2020. ncbi.nlm.nih.gov

23. J. A. Kellum, P. Romagnani, G. Ashuntantang, *et al.*, "Acute kidney injury," *Nature Reviews Disease Primers*, vol. 7, no. 1, 2021. nature.com
24. International Society of Nephrology, "Chronic kidney disease and the global public health agenda: an international consensus," Nature Reviews, 2024. nature.com
25. T. H. Yeh, K. C. Tu, H. Y. Wang, and J. Y. Chen, "… acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease," *International Journal of Molecular Sciences*, 2024. mdpi.com
26. Y. Gorelik, Z. Abassi, N. Bloch-Isenberg, M. Khamaisi *et al.*, "Changing serum creatinine in the detection of acute renal failure and recovery following radiocontrast studies among acutely ill inpatients: Reviewing insights regarding renal functional reserve gained by large-data analysis," 2022. ncbi.nlm.nih.gov
27. S. Spencer, R. Desborough, and S. Bhandari, "Should Cystatin C eGFR Become Routine Clinical Practice?," 2023. ncbi.nlm.nih.gov
28. F. C. Luft, "Biomarkers and predicting acute kidney injury," Acta Physiologica, 2021. wiley.com
29. L. E. Thompson and M. S. Joy, "Endogenous markers of kidney function and renal drug clearance processes of

filtration, secretion, and reabsorption," Current opinion in toxicology, 2022. nih.gov

30. L. A. Inker and S. Titan, "Measurement and estimation of GFR for use in clinical practice: core curriculum 2021," American Journal of Kidney Diseases, 2021. ajkd.org
31. A. M. Aklilu, "Diagnosis of chronic kidney disease and assessing glomerular filtration rate," Medical Clinics, 2023. [HTML]
32. M. G. Berenji, H. G. Berenji, S. Pashapour, *et al.*, "Serum Netrin-1 and Urinary KIM-1 levels as potential biomarkers for the diagnosis of early preeclampsia," *Journal of Obstetrics*, vol. XX, no. XX, pp. XX-XX, 2022. [HTML]
33. L. Ziegon and M. Schlegel, "Netrin-1: A modulator of macrophage driven acute and chronic inflammation," International Journal of Molecular Sciences, 2021. mdpi.com
34. B. Leszczyńska, M. Buczyński, A. Deja, "The usefulness of urinary netrin-1 determination as an early marker of acute kidney injury in children after cardiac surgery," Archives of Medical, 2024. nih.gov
35. B. Bazargani and M. Moghtaderi, "New Biomarkers in Early Diagnosis of Acute Kidney Injury in Children," 2022. ncbi.nlm.nih.gov
36. J. Pedroza-Díaz and S. Röthlisberger, "Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies," 2015. ncbi.nlm.nih.gov

37. V. Sirolli, L. Pieroni, L. Di Liberato, A. Urbani *et al.*, "Urinary Peptidomic Biomarkers in Kidney Diseases," 2019. ncbi.nlm.nih.gov
38. S. Lambrecht, M. Speeckaert, and M. Oyaert, "Optimization of screening strategy for chronic kidney disease by urine test strips using the albumin-creatinine read-out," BMC nephrology, 2025. springer.com
39. G. Résimont, L. Piéroni, E. Bigot-Corbel, E. Cavalier, "Urinary strips for protein assays: easy to do but difficult to interpret!," Journal of …, 2021. [HTML]
40. V. H. Nguyen, F. Khan, B. M. Shipman, *et al.*, "A semi-quantitative assay to measure glycosaminoglycan degradation by the urinary microbiota," *Frontiers in Cellular*, vol. 2022. frontiersin.org
41. H. Yin, A. Shi, and J. Wu, "Platelet-activating factor promotes the development of non-alcoholic fatty liver disease," *Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 2022, pp. 1-12, 2022. tandfonline.com
42. A. Dalbeni, M. Castelli, M. Zoncapè, P. Minuz, "Platelets in non-alcoholic fatty liver disease," Frontiers in…, 2022. frontiersin.org
43. P. K. Marie, N. W. Fowlkes, V. Afshar-Kharghan, *et al.*, "The provocative roles of platelets in liver disease and cancer," *Frontiers in …*, 2021. nih.gov
44. T. Kakegawa, K. Sugimoto, H. Kuroda, *et al.*, "Diagnostic accuracy of two-dimensional shear wave elastography for liver fibrosis: a multicenter prospective study," *Clinical Gastroenterology and Hepatology*, vol. XX, no. YY, pp. ZZ-ZZ, 2022. cghjournal.org

45. D. H. Lee, E. J. Cho, J. S. Bae, J. Y. Lee, S. J. Yu, H. Kim, *et al.*, "Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis," *Clinical*, vol. 2021, Elsevier. cghjournal.org
46. J. Xu, L. Zhang, W. Wen, Y. He, T. Wei, Y. Zheng, X. Pan, "Evaluation of standard breast ultrasonography by adding two-dimensional and three-dimensional shear wave elastography: a prospective, multicenter trial," *European Journal of Radiology*, vol. 2024, Springer. springer.com
47. Z. Liu, Q. Ren, H. Mu, Y. Zeng *et al.*, "Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD," 2024. ncbi.nlm.nih.gov
48. Y. Wu, J. Zhou, J. Zhang, and H. Li, "Cytokeratin 18 in nonalcoholic fatty liver disease: value and application," *Expert Review of Molecular Medicine*, vol. 2024, Taylor & Francis. [HTML]
49. J. Chen, J. Hu, J. Zhuang, Z. Li, S. Peng, "Diagnostic Value of Serum Cytokeratin 18 for the Staging of Liver Inflammation and Fibrosis: A Meta-Analysis," Journal of Clinical …, 2025. wiley.com
50. X. Zhang, J. Li, L. Jiang, Y. Deng, L. Wei, and X. Li, "Serum Cytokeratin-18 levels as a prognostic biomarker in advanced liver disease: a comprehensive meta-analysis," *Clinical and Experimental …*, 2024. springer.com
51. R. Rodríguez-Calvo, J. Moreno-Vedia, J. Girona, D. Ibarretxe *et al.*, "Relationship Between Fatty Acid

Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk," 2021. ncbi.nlm.nih.gov

52. Y. C. Lu, C. C. Chang, C. P. Wang, W. C. Hung *et al.*, "Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus," 2020. ncbi.nlm.nih.gov
53. S. Ishimura, M. Furuhashi, Y. Watanabe, K. Hoshina *et al.*, "Circulating Levels of Fatty Acid-Binding Protein Family and Metabolic Phenotype in the General Population," 2013. ncbi.nlm.nih.gov
54. H. L. Li, X. Wu, A. Xu, and R. L. C. Hoo, "A-FABP in metabolic diseases and the therapeutic implications: an update," International journal of molecular sciences, 2021. mdpi.com
55. J. Moreno-Vedia, J. Girona, D. Ibarretxe, L. Masana, "Unveiling the role of the fatty acid binding protein 4 in the metabolic-associated fatty liver disease," Biomedicines, vol. 2022. mdpi.com
56. C. Patel, K. Chaudagar, A. Mehta, and T. Gandhi, "Future Directions and Emerging Research in Metabolic Syndrome," in *… for Metabolic Syndrome*, 2024, Springer. [HTML]
57. T. A. Nyawo, C. Pheiffer, S. E. Mazibuko-Mbeje, "… adipose tissue to reduce cardiovascular disease risk in patients with metabolic diseases: oxidative stress and inflammation emerge as major therapeutic …," Antioxidants, 2021. mdpi.com

58. M. Mussap, A. Noto, V. Fanos, and J. N. Van Den Anker, "Emerging Biomarkers and Metabolomics for Assessing Toxic Nephropathy and Acute Kidney Injury (AKI) in Neonatology," 2014. ncbi.nlm.nih.gov
59. T. Larsen, E. J. See, N. E. Holmes, and R. Bellomo, "Estimating baseline creatinine to detect acute kidney injury in patients with chronic kidney disease," Nephrology, 2023. wiley.com
60. R. M. Ahmed, M. A. Khalil, A. H. Ibrahim, H. M. Eid *et al.*, "Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease," 2019. ncbi.nlm.nih.gov
61. Y. Liu, K. Xu, Y. Xiang, B. Ma, H. Li, Y. Li, and Y. Shi, "Role of MCP-1 as an inflammatory biomarker in nephropathy," *Frontiers in …*, 2024. frontiersin.org
62. A. A. Pérez-Arias, R. A. Méndez-Pérez, C. Cruz, *et al.*, "The first-year course of urine MCP-1 and its association with response to treatment and long-term kidney prognosis in lupus nephritis," *Clinical*, vol. 2023, Springer. [HTML]
63. G. Ruacho, R. Lira-Junior, I. Gunnarsson, *et al.*, "Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus," *Lupus Science & Medicine*, vol. 2022. bmj.com
64. D. Maria Tanase, E. Maria Gosav, S. Radu, C. Florida Costea *et al.*, "The Predictive Role of the Biomarker Kidney Molecule-1 (KIM-1) in Acute Kidney Injury (AKI) Cisplatin-Induced Nephrotoxicity," 2019. ncbi.nlm.nih.gov

65. X. Zeng, D. Hossain, D. G. Bostwick, G. A. Herrera *et al.*, "Urinary β2-Microglobulin Is a Good Indicator of Proximal Tubule Injury: A Correlative Study with Renal Biopsies," 2014. ncbi.nlm.nih.gov
66. M. Hassan, M. M. Aboelnaga, M. Al-Arman, "Urinary cystatin C as a biomarker of early renal dysfunction in type 2 diabetic patients," Diabetes & Metabolic, vol. 2021, Elsevier. [HTML]
67. M. A. Khusainova, "Cystatin C is an early marker of decreased kidney function," Oriental Renaissance: Innovative, Educational, vol. 2023, 2023. cyberleninka.ru
68. M. Indikar, B. Tonsalli, S. Patil, D. Sinnur *et al.*, "Study of Serum Cystatin-C Levels as a Biomarker and Urinary Microscopy in Severe Kidney Damage," Medica, 2024. medicainnovatica.org
69. C. Zou, C. Wang, and L. Lu, "Advances in the study of subclinical AKI biomarkers," 2022. ncbi.nlm.nih.gov
70. M. Ostermann, B. J Philips, and L. G Forni, "Clinical review: Biomarkers of acute kidney injury: where are we now?," 2012. ncbi.nlm.nih.gov
71. M. Yousef Almulhim, "The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review," PloS one, 2025. plos.org
72. D. Cottam and G. Azzopardi, "Biomarkers for early detection and predicting outcomes in acute kidney injury," *British Journal of Hospital*, 2022. magonlinelibrary.com

73. L. G. Cantley, C. R. Parikh, and ASSESS-AKI Consortium, "Longitudinal biomarkers and kidney disease progression after acute kidney injury," JCI, 2023. nih.gov
74. T. Papadopoulos, M. Krochmal, K. Cisek, M. Fernandes *et al.*, "Omics databases on kidney disease: where they can be found and how to benefit from them," 2016. ncbi.nlm.nih.gov
75. M. Cui, F. Deng, M. L. Disis, C. Cheng, "Advances in the clinical application of high-throughput proteomics," *Hypothesis in Medicine*, 2024. nih.gov
76. L. Yang, S. Pijuan-Galito, H. S. Rho, A. S. Vasilevich, *et al.*, "High-throughput methods in the discovery and study of biomaterials and materiobiology," *Chemical Reviews*, vol. 121, no. 10, pp. 1-27, 2021. acs.org
77. V. Prajapati, M. Verma, G. S. Kumar, and J. Patel, "High-Throughput Preclinical Models and Pharmacoproteomics," in Recent Trends and ..., 2024, Springer. [HTML]
78. G. Cullaro, A. S. Allegretti, K. R. Patidar, E. C. Verna *et al.*, "Applying Metabolomics and Aptamer-based Proteomics to Determine Pathophysiologic Differences in Decompensated Cirrhosis Patients Hospitalized with Acute Kidney Injury," 2024. ncbi.nlm.nih.gov
79. A. Ortiz, "Proteomics for Clinical Assessment of Kidney Disease," 2019. [PDF]
80. V. Lopez-Lopez and F. Perez-Sanz, "Proteomics in liver transplantation: a systematic review," Frontiers in…, 2021. frontiersin.org

81. M. M. Rinschen and J. Saez-Rodriguez, "The tissue proteome in the multi-omic landscape of kidney disease," Nature Reviews Nephrology, 2021. [HTML]

82. M. P. Chantada-Vázquez and S. B. Bravo, "Proteomics in inherited metabolic disorders," *International Journal of …*, 2022. mdpi.com

83. V. A. Luyckx, A. D. Rule, K. R. Tuttle, P. Delanaye, *et al.*, "Nephron overload as a therapeutic target to maximize kidney lifespan," *Nature Reviews*, 2022. uliege.be

84. H. Scholz, F. J. Boivin, K. M. Schmidt-Ott, *et al.*, "Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection," *Nature Reviews*, vol. 21, no. 2021, pp. 1-16, 2021. [HTML]

85. B. M. Klinkhammer, S. Buchtler, S. Djudjaj, N. Bouteldja, *et al.*, "Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease," Kidney International, vol. 2022, Elsevier. [HTML]

86. A. Verma, V. C. Chitalia, S. S. Waikar, and V. B. Kolachalama, "Machine Learning Applications in Nephrology: A Bibliometric Analysis Comparing Kidney Studies to Other Medicine Subspecialities," 2021. ncbi.nlm.nih.gov

87. C. Baciu, C. Xu, M. Alim, K. Prayitno *et al.*, "Artificial intelligence applied to omics data in liver diseases: Enhancing clinical predictions," 2022. ncbi.nlm.nih.gov

88. L. Yao, H. Zhang, M. Zhang, X. Chen, J. Zhang, and J. Huang, "Application of artificial intelligence in renal

disease," *Clinical eHealth*, vol. 2021, Elsevier. sciencedirect.com

89. R. Sawhney, A. Malik, S. Sharma, and V. Narayan, "A comparative assessment of artificial intelligence models used for early prediction and evaluation of chronic kidney disease," Decision Analytics Journal, 2023. sciencedirect.com
90. C. C. Wu, M. M. Islam, T. N. Poly, and Y. C. Weng, "Artificial intelligence in kidney disease: a comprehensive study and directions for future research," Diagnostics, 2024. mdpi.com
91. D. Zhao, W. Wang, T. Tang, Y. Y. Zhang, and C. Yu, "Current progress in artificial intelligence-assisted medical image analysis for chronic kidney disease: A literature review," *Computational and Structural Biotechnology Journal*, vol. 2023, Elsevier. sciencedirect.com
92. Q. Yuan, B. Tang, and C. Zhang, "Signaling pathways of chronic kidney diseases, implications for therapeutics," Signal transduction and targeted therapy, 2022. nature.com
93. L. Qu and B. Jiao, "The interplay between immune and metabolic pathways in kidney disease," Cells, 2023. mdpi.com
94. X.H. Wang, W.E. Mitch, and S.R. Price, "Pathophysiological mechanisms leading to muscle loss in chronic kidney disease," Nature Reviews Nephrology, 2022. [HTML]

95. S. Zhang and F. Cui, "Global progress, challenges and strategies in eliminating public threat of viral hepatitis," Infectious Diseases of Poverty, 2025. mednexus.org
96. M. A. Odenwald and S. Paul, "Viral hepatitis: Past, present, and future," World journal of gastroenterology, 2022. nih.gov
97. F. Cui, S. Blach, C. M. Mingiedi, M. A. Gonzalez, *et al*., "Global reporting of progress towards elimination of hepatitis B and hepatitis C," The Lancet, vol. XX, no. YY, pp. ZZ-ZZ, 2023. bris.ac.uk
98. K. B Bufkin, Z. A Karim, and J. Silva, "Review of the limitations of current biomarkers in acute kidney injury clinical practices," 2024. ncbi.nlm.nih.gov
99. N. Parvin, S. W. Joo, J. H. Jung, and T. K. Mandal, "Multimodal AI in Biomedicine: Pioneering the Future of Biomaterials, Diagnostics, and Personalized Healthcare," Nanomaterials, 2025. mdpi.com
100. S. J. Patil, V. M. Thorat, A. A. Koparde, R. R. Bhosale, "Theranostic applications of scaffolds in current biomedical research," Cureus, 2024. cureus.com
101. R. Dave, K. Pandey, R. Patel, N. Gour, "Biological scaffolds in 3D cell models: driving innovation in drug discovery," Stem Cell Reviews and Reports, vol. 2025, Springer. [HTML]
102. J. Rajendran and R. Esfandyarpour, "Revolutionizing personalized health: The frontier of wearable biomolecule sensors through 3D printing innovation," Biomedical Materials & Devices, 2025. springer.com

103. V. Radišić Biljak, L. Honović, J. Matica, B. Krešić *et al.*, "The role of laboratory testing in detection and classification of chronic kidney disease: national recommendations," 2017. ncbi.nlm.nih.gov

104. P. Halfon, F. Imbert-Bismut, D. Messous, G. Antoniotti *et al.*, "A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease," 2002. ncbi.nlm.nih.gov

105. R. V. Yewale and B. S. Ramakrishna, "Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?," Hepatology Research, 2023. [HTML]

106. S. K. Asrani, N. Shankar, B. da Graca, "Role of novel kidney biomarkers in patients with cirrhosis and after liver transplantation," *Liver*, vol. 2022, Wiley Online Library. wiley.com

107. Y. Wen and C. R. Parikh, "Current concepts and advances in biomarkers of acute kidney injury," Critical reviews in clinical laboratory sciences, 2021. [HTML]

108. B. N. Swanson, "Delivery of High-Quality Biomarker Assays," 2002. ncbi.nlm.nih.gov

109. H. Wazir, M. Abid, B. Essani, H. Saeed, and M. A. Khan, "Diagnosis and treatment of liver disease: current trends and future directions," Cureus, 2023. cureus.com

110. N. Nishida, "Advancements in Artificial Intelligence-Enhanced Imaging Diagnostics for the Management of

Liver Disease-Applications and Challenges in Personalized …," Bioengineering, 2024. mdpi.com

111. F. Yao, W. Gao, L. Li, Y. Huang, W. Sang, "Nanomedical Strategies for Kidney Disease: Diagnostic Innovations and Therapeutic Advancements," Advanced Healthcare, 2025. [HTML]
112. Y. Ozarda, "Reference intervals: current status, recent developments and future considerations," 2016. ncbi.nlm.nih.gov
113. A. Sharma, D. Ram Pokharel, and G. Dhakal, "Establishment of dry-chemistry-based reference intervals of routine liver function tests for the adult population of Gandaki Province, Nepal," 2024. ncbi.nlm.nih.gov
114. L. Martinez-Sanchez, C. M. Cobbaert, R. Noordam, N. Brouwer *et al.*, "Indirect determination of biochemistry reference intervals using outpatient data," 2022. ncbi.nlm.nih.gov
115. A. A. Isaksen, A. Sandbæk, M. V. Skriver, *et al.*, "Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses," PLOS Global Public Health, 2023. plos.org
116. J. Velev, L. Velázquez-Sosa, J. Lebien, H. Janwa, "Modeling Multivariate Distributions of Lipid Panel Biomarkers for Reference Interval Estimation and Comorbidity Analysis," Healthcare, 2025. mdpi.com
117. Y. Wen, S. Cheng, L. Gou, W. Zhou, Y. Li, *et al.*, "Serum LCAT as a Gender-Neutral Biomarker for

Early Osteoporosis: A Multicenter Cohort Validation Study," *Journal of General …*, 2025. tandfonline.com

118. P. Kumar, K. Singh, A. Garg, A. B. Urs *et al.*, "Salivary IL-8, CYFRA 21-1, and CD44 for early detection of oral squamous cell carcinoma: a systematic review and meta-analysis," Clinica Chimica Acta, 2025. [HTML]
119. N. Bogavac-Stanojević and Z. Jelić-Ivanović, "The Cost-Effective Laboratory: Implementation of Economic Evaluation of Laboratory Testing," 2017. [PDF]
120. M. M. Kaminski, O. O. Abudayyeh, J. S. Gootenberg, *et al.*, "CRISPR-based diagnostics," *Nature Biomedical Engineering*, vol. 5, no. 11, pp. 1001-1014, 2021. nature.com
121. FA Castelli, G. Rosati, C. Moguet, C. Fuentes, "Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests," *Analytical and Bioanalytical Chemistry*, vol. 414, no. 1, pp. 1-15, 2022. springer.com
122. J. Wekalao, N. Mandela, O. Apochi, C. Lefu *et al.*, "Nanoengineered graphene metasurface surface plasmon resonance sensor for precise hemoglobin detection with AI-assisted performance prediction," Plasmonics, 2025. researchgate.net
123. A. Armghan, J. Logeshwaran, S. M. Sutharshan, "Design of biosensor for synchronized identification of

diabetes using deep learning," *Results in …*, vol. 2023, Elsevier. sciencedirect.com